var title_f13_20_13632="Posterior shoulder dislocation with blocked external rotation";
var content_f13_20_13632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/54900/Post_blocked_ext_rotation.mp4?title=Posterior+shoulder+dislocation+with+blocked+external+rotation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior shoulder dislocation with blocked external rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC7NrAOVt0bPqaqtNe3GS7sFrCbW/MkMel2kly/TKrkVN/Z2qXq79SuxaRH+BTg1zNtnVaxen1DT7Dm6n3Sf3FOTTIrvVdS40m18mI/8tJuOKLO002y4toPtE3/AD0cZq4bm4k437E9BUsasEOnQR4fWLuS4l/uIeKnvJYZbZre3t1SEjHPWoVUYyeTTZW4o5h8tzy7Sd9tfzR85DkY/Guwtp3CDIP4Vz1/D5GvzkdC24Vt2zfKBRJ6Dgi99oDDBDZqUBniyCcVXHSrEDbVI7UoPuKoVkAB++fzrqfB2nvqWpIGJ+zx/M5/pXNNGpPHU16r4QsRp+jRMBh5fmarhHmdxSdom/cyDAVeEUYAqi7knrUkj5quxrpObfUQk+tRsT607NNbmgADe5pGJpuKKBBk+tJz6mloxQAnPrRkkcmlApCKAGEn3rjviunmeDrv1UbhXZEYrkvih/yKdyD/ABECkB81tI3HJzU0crbfvH86guVKSEUI3FJgiybmRP42x9aT7UzDG41WdsimKaLFXdydpHP8TfnUbM395vzoJ96Yzc0A2LvbP3m/OlMjD+JvzqMmkJpkEgdv7zfnXV+DoGMr3DZ2gYGa5SFC7ADvXoeiQCGwjQenNDY0bUZPGCauROR3NUIzgVajbpU3KRpRSN6mr0EjdjWTE/NXoHGRRcdjTR2/vGn7mYfeP51DEQavQxqw60wSIBx3YmnKsjdyK1be2iOM4rQisIXH3gPxpiZzgs9/MhqvNpqN90sPoa7JdFhfrMPzqePQ7cceZmgLo89OmXCf6m5lX8afGdet/wDUXLED1NeijQ4v4WWkbw/v+661VkFzg49Z8QxH98nmj2rSt9emYD7bauB3IrpX8P3MfMRDVTn0TUpG/wBSMUrCK0N3o910lkhk/wBur9taHO62nSUexqqPDNweZYQami0O5jP7lGjx6HFFgNuxlZA0NxEfLcYNct4ptjbbgNxj6git+LzrdMXNygUddzc1FcataMPKj2zv09aYHnOq67bxaLLAhbzQhXmvMdIzLqkYY4DScn8a7z4iQxwXBlRNiyr0x3rhtGjxKCTznrWb0uXukj0j7e8S+XYQx26f7K4NV2VpWzM5c+9OxgmnrXK23odNrCeTJsPljYPWrljFGsarKSxxUayAgIXAAprXCKcRgsfWtbJIzbcnoWJF2k46VBKflNMSV3++aSUnaazk7vQuKaWpyGvpt1NX/vCrVscgGofELL5kZBBYHpT7Jt0akUSCO5pIamiOQ1Vk6VYtz8xFRHQqS0Lelw/aNQgixnc4FetxEJGIeyjArzjwXB53iCEkcIC1eiSkeYTXTSRzVOgN3FRNUg5o2+tbGRCaTHepmXim7eKAGYppFSYpODwuSfYUANwaUVetNLuLo/dMaerCrD6FsOBcqzelOwjIIpQK3IvDMrrl5wntimy+HJYz8k4b8KLCuYjDAzXFfFRwPCkp/wCmqivQb7TxZxlrq6ijUDua8a+KOv2lzbDTbKUTfOHdh0GKmVkVG541qKfNkVQzita8GWNZrqBUxZUkRZooNFWQGaKKKACijtTlGTQBp6Dam61CCIfxuBXqkPhXUgo+yuhXHG6uI8BWhuNbt1A5BzXvsA8oIvbGKi6uadDze40fVrLm4ty49UFRRuQ22VGRh2Ir1tHO3y3AYdsiuC8cTwRamttFGPMC7mI7UOwJX2McSYqaO4IxWcJOcVMjA1N0VZo1EvinSpF1d06ZrPjXPWrMVurdadhE58QXK/dHFNPiO7HciporNCORVhNPgbqlNC0M8+J71ejNR/wluoD7rkVqrpVqeq08aRa9k/Siw7GSPGOqDpIalTxpq4+7JWj/AGNB/cFI2j2wH3aLBYqp4310fdnH5VMPHfiDH/HwPypx0eL+EYpBpCe1FgsMfxvr79bgf981Xl8T63Pw104z6VdXSI+4zU8WmRKc7BT1FoYv2jULlv3ssj/WtSws79SskRww5xWlFbxp0XFXrY4IpCMjxvpsmteGGljTF7bfeUfxCvKbdJFiTZ8rZyc19A2pQtlgMEYI9RXB+LvCwsb8XFsubSY5GP4TTlsVGzZEeppy0gx1NPCZGTwB3rktc6irIvzkmkBx04qRT9om8q2HmN3I6CnXVotvxLLuk9B2osLmSK9xqFvapmR8t6Cuc1TX7iUMtsNieprSu7JGJbBJ96x7u32A4WmO2hjB5JHLSOWY981vaO263x6GsWRVEvy9DzWroxwWX1pvVExNtDxU9t/rgPWoEqWA4nWs47ly2O28AQ/8TCeU9lwK7C6XD5rn/A8Xl2bSEfM0mPwrprlcmuyCsjjm7sqgtt+Wno+7qOaagIalwd2FGTVogmGGpNhJwBk1es9JnuAGZtg963bLS4rbBb5296dhXMSx0eWcgy5VK3rXTbW1GQgJHc1dBCjpgVBOWlUhaZLZlatqbITHBgAelLots4X7Vcfeb7oNXrbSYt3mT8+1Z3ijXrXSY9m5fMA4GelIncv3l8tnDJPdSKkSDJJNeUeJfipmV4NFXfjjfXC+N/Gd/wCJrw6Vp8zi2DfvXU9faqdtpyWluqIOcck965a1ZR0R24fDc+rI9a1vU9WkZry5kOf4QeK5S/QRoxxyeprpLxAuT3rnNTy2axhNvc6Z01FaHPzjk+lUJBWlMvWqMo5NdSZyMqMKZU7CmFatMyaI6KdiiqFYbUsIywpgFWrWIu6qoyzHAFJjSPR/hTYlr17ph8qcCvUHnLsADjBrF8FaX/Z2jwoRhyuWPua3EiXd9KzLSNGCdflbOSBXmHiSdbjXLqZW3Bm7fyruNcuhpuh3VwPv7SqfU15akmVBzknk59ayqOyN6SRbTpk1Yi5NVIjnHNXYMCsVJo20ZZQFcEVahuUQ/OcVHA6Dg1bVLVx86irjUtuQ6SLEF5b93q0mo2gxlxWd9iticx4zUkFvbFtsiqD64rWNRMxlSaNVNWsV6mpl1mz/AIRmobfSLaQAr5dXk0WJRw8YrVGZGupWz9iKkW7tmqQaRBjmeP8AOl+wwRniSMmqEN82E9BS/IegpDGinAIoUKBxQFg4zxSjrRRQJgachwaQ0lAky5DIcjNan7u8sWtpwGVhx7GsHecfLwatWjyREMz7uelAbank8/izT4Icq5kk7KKZo0uq+KrnYjfZbEH5nHHFeX7vnb616P4KvHfTViicqAcMBWUoqKNYycmd401rpVsLLShvccPKe5rNZSSWc7mPJJpyosSruPzEUABmALYFY7m6SI3UMtZl5ECOlbEjAjYoGB3qjdKNtDHuchcx+XIFHVeKt6Y2JhTdRjxcE+tFp8sgNK4uU6BDxUsRxKh96qo/A7U9JQXVUOTkUoxbZUmkj1rw6nl2Fv2JGTW9KMrWPpq+XbQDuFFbqxmYqo6muyKsrHDLe5VtraS5nCRLk9z6V1Gn6TDbANIAz+9R2qJaQhExvPU1o2rbh8xzVkthJGrDKHGPSqk0s0J4BIq5cI0Q3JyO4poKzxED73pQQymt28p2YINS28kisRgH61G0ZjcE9c0Xcu2MbPvPxQHQzvGvieHw9oE9/Ny6jCKO7V826lP4k8VXMlxI/lRzHP3ugrufjZqvn6vY6OjZWNfMkHvXFpfSwnCMQPQVy1qyi7HbhsM5e8zQ0jQ49Ktti/NIeWb1qacECqSavJj5jmnPfq4964m1J6nopcqsijexs2etYF7bnnIroprjIPSsu7YNmtIKxElc5S6i2uRWZNGdx4robxMvmqDw57V0xkccoamK0ZqMqRWrLBVOSMg1qmYuJVK0m2pihpVSjmFyjEjyenWuu+H+jnUNbjZ1zFD8x+tc7DGSQByx4Fe2eAdHXS9KjeRf3snzGp5iuU6kIIY1QdhT1Hy9OTUWS7bjT42w5JPAFAzi/iTf+WtvZK3+2wrh0m5q34tvjf69cS7sqp2j8KzY6wqvU3pKyNBLggVZjuDWYDipFesmapGulz71J9qPrWSsvvTxL71JZqi9ZTkManGolhhjWH5tHmUR0Bs2jfTfwTuo9M1ftbe+uUDLett+vSuYEp9a0dJ1FrWddxJjJwa3hNp6nPUgnsdLDpU55e7c/jV6KwKf8t2J+tEN5CVBGcGp1nDfdUn6V1q3Q47E0cTIAC+anU1BGszniNvyq0ltcEcRN+VMYCiplsrojiJqeNOu2/5ZmiwivmirP9nXCn5gF+tRSQ+V990/A0ARqeRxUq4VgxP4VWa4CcIMmmCQuw3daAPmM/6xvrXYeAbjZdyRE8HBFcky5kb61teGJfI1WE5wCdp/GpnrEKbsz1f/AEcOHuNxB9KaZI2YiPOO2aaQGhHcVCvyuD7VypnXbUsA1FccrS96iupFjX5j+FJXbLdkjE1JPmzVWLO4bQSavXW1k82ZhHEO571zmpa/HHmKwX6ua6I0r7nNOtZ6G1cXkcCZncA/3Qak8JzS614jtbeJcQhtzfQVyNjZXmqT7mzg9Sa9k+F+gxWCyXIXMg+XdWistDL3pas9GjXawC9uldLaqILcSN94isbSoPOm3MPkXk1pXl0FYIvJ9PSmiZDZrnaTknNWtLvj521j1rIkyfmaq8Exim3E96ZJ6CGDpVMjy5sr0NN02fzYFOasTLmnuJojmw3NZs8oW6iTtnNXy20c9K5nW71IReTqcC3hZifwqW7IFq7Hgvim5Oo+N9VuichH8tT7CqMlFp++E9y3LTys+fYmnsnFeZVd5XPZoLlhYpSMRUDTspq1LGSaqyQk1KNWR/a2PFBctQYsdqeqgCtEzOzbKs0eaqyJgdK0XGaqSg1abMpIzpU9qpTx81qSiqkoz1FaKRlKJmslCpzViReadbW8lxPHDECXc4FVe5FjofAeinVNVSRx/o8J3E+pr2VQBhFGAOAKyPC2lR6PpMUOP3hGWPvW0n6mmmSxegrP8TXo03QbibPzuNi/U1pY3EAfjXC/E2//AHttp6n7o8xhSYROEPOSeWPJPvTlpp64FOWud67nVFWJM0bqZQTxSGPD04SVBmjdSY0TmQ0CTFVy1JvoBltZKmR8is9XqZJKaYro7Hw/r9tZxiO8iMm3pxXUQeN9LhUeXYMW+lebaZJGLyLzACpOOa720tbXgeSp/CumlJy3OStGz0NMfEFf+WGnDHuKQ+O79/8AVWCj8KI7a27QqPwqykUS9EUfhW+pi9CqfFesy/ctlH4UDVfEFx90COr29Bwo59hU8cN3N/qY2x60AZJh1Ob/AI+bth9DT1s1Tl5HZvUmth9PljXdczog9zVCe60+I7EkM0n+zTC5AQF6HioGk+bg0+V9/ONo9KrFhuGKBngctuVuZFx0Y1esIGWRXxypzXWPo0c0zNgdaZcWcNqMuQAKN4kvSWp0lhJ5tnGe5UVJJDJGu9wAnqaxdM1GPyAsWXI4GKkubny0Mup3BWPqIgawjT1sbuqkrlx7lnOLdd3q3YVi6tq9tp+d7Caf0B4FYms+KJZwYNPHlQ9OOpqDSvDd5fkXF18kR5yeprRQUDJzlUehRvL+81ef+Ir2UdBV/T9IRMNPy3pXSw6bb2UYSCMZ7k1WlCib5Rjipc77FxpqO5f02MKgCKFHQAV7B4cs/sul28WPncbj+NeX+FYDearBBjjIY/SvarXZB+9b7qjCinTV9QqysrI0HmFhaLFGAZTyapx5Y72OWPJqsZWlkMjn5ielSo7elanPe5dCiRME1RvLVihKE5HNWY5B0NTI+CAeRQMs+GrtvJCPng4rpPMXb8xrmdJTyr2RT9xvmWt5QrDLU0SyG7mzGRjArg/iVdLp/gq+deJLkiIfjxXdXWHUgDivJvjjc+Xp2kWef9ZMSR9BUzdosqmryR51ZJ5drGn91QKlK1Aj4HWpS+a8pu7PaW1iJxzULJmpnNRF6Gi0M8jJpDb471IJsdaa9wB1pxJkVZoiOhqpIlXZJgxqCTDDitUYPUzpI+tVJE5rSdarSJTuQZrpjJPSu7+G2gb3Op3SYUcRA/zrC8PaM+sarHbqp8oHdIfavY47dLaGO3hULGgwAK0jqZSYw/M/+zUyDmj5VP6UuR2q7WIZJEQpaRvuKMk14t4jvjqGtXVyTnLED6CvVvFt1/Z/he5lzh2XYPqa8UDZ69e9KS0HDclDU8GoAwFBcVk0b3uTl6Yz1Cz1G0lLlY7k5fmk31AZKYZKXKHMWC/vTS4qsZDUbOaagJyLwf3qVWzWcshFTxyU+USZpwSEEHuDXpOj3AltInAyxUCvLYnzxXceGddjsbNVeMuy9KumtSKmx3NraXUxBCECtBLCCAZvLhV9s1yknibU7vItU8tD04qBbLUL5t11K5BrpOU6y41vSbAYgxK4rLuPE2o3Z22cQRD0OKgtNEt4vmkGT71ooscQxEoFAGelnc3J3308hz2zVpLeGBcQoM+p61YaRuh5NMO8jpgUxFWUZHNVR/rVA9asTnnFQIMODUlnB32omzhJRSztwFFZ1vpt5qT/AGjUpDBAOdp4zU89za2GZblxJKOi+lc9q+vXV+dqsVi7AU4LlWpnKV3dG5f61Z6dH5GnxguON9cxcXM1/P8AvpCdx7npVEhiwGeT3NXZdLuo7dZ0IePrx2qritc6vQdFtrbZLMvmv15rqN25flGF7CuR8L6qXVbe6B3D7rV1atwMdDXLO9zrpKJXuOtY8wxN9K1rk5JxWXdA+eoQZd+AB3NQn0NHud/8M7DfcS3LD5QMZrvriYOwVB8o6Vn+ENLbTtBgjlXbLIoLVsiGNBz1rrgtDiqO7sRQR7hufiraYIAAquxGRzwKtxSIRiqIFEaZ96eQccCnBVPI60vKKWYgAetAEUUsscyEqcA10MLiQDNcrJrdvkpj23Yrd0qdZbdWU5oJZoTAbCa8J+OlwW8QaTATyiF8fWvcpGBxz0r54+NE5m+Ica54itgv45NZ1fhNaPxGAhGak3VVQkgYqQHA5rzWeytiRjUTGkZ81G71SBsR5MVTmnHrUkrZqhMuG561cUjOUmOE+T1qZJMiqYTrilViOlU0ZplpietMWN5pUiiUtI5wqihORlvyr0r4c+GhGv8AbGoR84/cqR+tEVd2FOVlqafhjQ00PTFDKPtUoy57itCQHtWkyPO7SP36D0qGSA56V0cuhy812Zu0lqsxR8gU8wsDwKnsoGabLdqGI8/+Ld4VitLFTjd87CvNWPNdT8TrkzeLZY85WJFUfXvXKZrNm0dgJxTGalY1ExoQ2DPiomk5oc8VCxxTsTceZTSb81XL80qvT5SeYnLUm6o91GaEFyQGpY25qAVIpwaLDuX4WrsfB8cc+7zBnBriIW5rtPBTfNJ9c0o6MJao72EIn+rSrQZgM9KrQkkDbV6C3LEGQ8V0pnPYYqtJ71aispSMn5V96Se9tbNMLy9Zc2oXl4dsPypQFjVmks7FSZJA8npms2S5luz8i7UqOGwG7fOS7e9WHJyI4h8x6YouKxVdOdo5qB/kJJ7VqXMS2NtmU5lYdKxpn/0dm7kgVL0LieJLZ3V3KWfcRnqahmiaNymMYru9ihsKAB7Vl32l77gso60oT5mE6fKtTlSr4yFzUkV9dRxtEjnyz1BrqYNEY4yvFXj4ZhuUV4ztcdR61cmluZxi3sYfhqK5+0JMts0sYODxXbLHLFGN6Ed/pV7TFj0+2SJAMAcmr0TfaJBEi72bgACs2ozNFzQepz8oIHALMeijqTXf/D7wQEZdZ1tRkcxRN2962/C3guC1Zb7U1Bccqh7Vs63dNKoSI7UAwAOlKNPlHOroTT3EG7cZFA9KrvcQv905rmZSQ5yTmprebBxmtTn3NssGOVxipo2A6DmqMAMuAua0re1K8tnimMnRhHHk/ePQVC8MtywRshT2q7BA4IkaMk9q0bWER/PIR5jfpQBnf2TapB5flAk9TUFgn2WRoVJA7V0DRbhleayb6ExTLIB3waCXoWbbd5w3HI6186/E0vL8QL2ZwQj8of8AZr6CubhIYWOfnK8CvKviZo/n+HbLV41y8T7ZCPQ1NRXiXRdpHnQbbSM9MGcUwtXm2PZT0Fdzniomc4NKcmmMOME1RLI3kz0qq24yAk8VLIm3OCcVCJYwPndc1RFxxJ3nHQ07Kg+57VNpljearcLDplvJM54yFOK9V8JfDaLTgt94jYGQcrCKpRZDkluYXw/8GTanKuoamphsYzlVYY3V6gyiZlSECO2jGFUd6nYtOqxxIIrVRwo707bgYUcCt4Qsc1SpzMi2jGFFJ5JPapPMA9qUXCetUSiBrbNT2cAjy7dFGT+FOMq4pZHH2K5I6+U+P++TSY0fNPia6+2+I9Tn6hrhtv0zWaTUs+fOfd94sS31qBqybuzeOw1jULGpGNQMaEJ6jGNQO1Pc1Xc1aM5MY7805GqB25p6GtbaGXNqWQ1KGqMU7rWdjREitT1aohTxQO5Ziau08GNgMfeuIiPIrtfCg2wg+potYLnoNtJtXOafNdysNqZqpancqir8YVeoFapmT3IILQyNvl5+taCKqDAAFMEhb7q8VYggeRsYPNAmRhJJWCRg5NasdtDpdq1xckGTHANWreGGwgMsuNwGa5DX9Te+nKqcRjtT2Dcq3169/dtIxO3PAqO9+WxQf3npkSjIxT9SPyQx+nNZTZcFrY40feP1q7boruM4qhzuP1pxuTEhx1rCM7am843Rp3dzFAm1PvUmlz+ZvUnkc1z7yu7ZPetnwpZ3Oo6kILNGckYY9hVyk5kwiom9aW0t5OsNvGXkY44r1Dwr4Yg0aAXF0BJdEZ5/hqXw9ottoNsGba90w+YntVq6vC7HJrWFPl1ZnUqX0RYurhpXwTkelZU8yLIVZKngk3ygZ61ZvYEZOV+bsa0WpzzOfmtxNKFRcsa1LDQN2C45rU0XT1BM0o+lbJnghXK4JqtBFWy0dI1GQAKsukEAwoBNZ11fXUpIiwq+9Ui10rjLq4PXFMV2actxJzz8vbFZkl4yNudqvIpwARk1Sv7UOpGOtSwJbfWo4zgtmtGWSK7tSyc964O6t5LaQnBK1o6Dfss/lE5Vh0pDNG+XfGB3HFOk02C+8Ny2FyP3cikH2p0hHnKD61eC/uCB0NO2gLRnlF98Ibxxu06/+U9Ae1ZjfBnxC2SLxTXrkl3qcYKW9sSg6EGqjS605yBMn0rJwj2OxV521PKG+DPifOBcLinR/BHxE5/fXqqK9ajPiBjhDIfqa0Laz1iXH2qcxr9aXJHsHtZHkUHwNuAQb3WMDuAcV0Gl/CjwxppEl5K1y6/3myDXpK6VEozPPI5+tRva2yfcTPuarlRPtGzDs47HTk8rRbJIQBjcq4oNu8r+bdyFz6E8VfuQFwEUAe1UZmIJHpQkS2KUC8A/SoJsAgDrnmgy85NNDLyT1PFMRWuTxkVnySYNajoCm31qjc25wSKTQ0yJbjjrVmGcMhQnhuDWY6tH1HFPjk44NQ3YpHhnie0Nj4gv4CMASsV+mayWOF5rv/ijp+27i1FV4YbHNefyck1nLyNI7ETmoHNSuahc00ORBIaqyNU8xqnI2TWsEc82J1NTxioUGTVqJaqRMUOApwFSKvFKFrM2sMAp3enFcUlJAx8XWu78PLsgj964aAZcD1Nd7pQ2og9FqkSdbYn5a1YI9/J6Vj6fyoretRkACqRDLNvEWYBBite3iWFdzdRVW1G0ZqhrmqeREUQ/Maq4WKviLU/McxI3FYEaljzTRumkLMetWlXC0mxoWIAOBVbVbqG3k8y4bCqAMVYQ7XBPaqV3aJqDMjoG9Ce1Q1dlxdtTmwMk/WoZ4STkDinI4ckg1espoS6x3PCE4JrljqdU4dUHh/w/ca1diG3VhHn5nxwK9o0LS7Hw1YrDaqpuCPnesLRtQsrCxWLT9nI5YdTUrX+85LcmuqKSRxyk3obU94XYktkmqj3HPJrMa6GOtRCcu3tVNmdjbs5szqc106lZYRk/SuHgnCSKx6Ct2HXrKKPazYaqiyJ6kl1q1zYzlGXMVQtrZkPyisjWNSW6bMXIrGm1BLVd0jAH0ptkrQ606nMThsgH0qRL8wr5p5OcAVg6brEV5DtXr3BqzcPlFHpRcDsdL1S3u1wflfvWoyxSLjivMYL029yrKeM12On6iJFXnk0XGWruyRwQQMVgSWDWd4ksf3M810ctwCABVecCaMqBTEVG5mVj0PSthF+QLWPCD5ig84OK1mfkCmCOX1Hxa+n38lrnG0+lWLXxhK4yNpri/HcfleJC3ZlrLt5TGw2kis2apnrEPidpODhavQ6ysnHmZrzG2vCQA1aEM5ByrEVNyz0yG4imAORmpjAHX5ea89h1OaLoSa1rHxGyEBzTTGbt1asueMg1j3ERU/Nn0rbtNdtplAfGferUkNpeJwVBqhHDNkB89jUTSYA+tdLqGhuAxiORXN3dnNDu3qeBSYXF88HvUqshIzWO8hXOOtNW8KnkcipuPc1pYY5AQRxWXdWrRHcg4px1IYweDTW1OJhtc0nYNjH12yj1XTJbWTHzj5T6GvEb62ls7qW2nUrJGcfX3r3ad0EhZDw1ch470Aalb/bbRcXUY+YD+IVL7GiZ5Y9V5OlWZAecghgcEelVZDikkNvQqTHg1UPWrExzVet47HNLcmiHSrsK1VhHSr0Q4FZy3NYIeF4pwWnKKfis2za1yFhxTDUzCoiOacSZE1qP3ifUV3WndF+grhrbhx9a7jTjiND6gVaM2dTp33RXRWQwB61zum9FrooWEcW9jgAVaRDLF7dra25Zj81cfczvcTF2Ocmp9UvDdzEA/IKitYt7dKGxosWsLFRxipJvk4zzU5+RKqSEsc0LYLjcEjjrWbd3rrKLaBhGTyTWvCmVc+grkdcYvqMqx53ggDFJoZziXDJISD3rThnSVeetYZbEjfWpY5Sp4NcbidykdNY3ctmw8tiV9K6ay1yCVQHyHHrXB29zu4Jq4rdx1pqbWjFKkpanfC7Ep+Q8VajmAHWuCt9TmtyMcita01yKQgSnYa2jNM5XScTrY5z1zxTJ4TOC0WCe4rJS8E/EJ3egqzBNLG3zZVvStonPJEcq3S8LlarfYmkfdMSx9621nZxyoPvUF1f2tqubiVE9s81RnsRWcDQSCSMEHuK3GuEdB82GPUGuQk8RG4cx6fCXHTdipoY7kqZbx9gPOM0DOojsHul/cspbrjNaOjSMrGKYFZV6Z71w8GrzW11G9qxIVuTnrXewXcGoQpcKAswGaAR0FpbOy+ZK4C+lWGAHyr09ar6ayXMYPmcjgjNaLRJEu5nHHQVSEzNhQC4PNWFyZDzUEAJkZvU5FTRndkj6UgWxyfjPRptQu1ltwC4XpXHzafe2rfvbd8DuBXoniO+bTZIbjH7vo1WdP1myvox5iowPqKktHmCXJQ4YEfUVbhuzng8V6XPoOk6iv3FVj6Vh3/gIYJs5foKho2Ul1OehveOelWUnik6nBqpe+G9Ws8/uWdR3FZMv2iA/vY3Uj1FTqh6M6cM68xyfkasW+q3cBxvPFcjHqDR9GNWk1V/4gDRcLHbweLbiLAkG4VaHiqxuBi5hPPXiuDXUIX4cbTQ2HGYXU+1NSYWO0nh0y+Ba1mCMex4rFvtJuYuYwJF9VrnzcTQHOD+FWLbxHNAcFmx70X7hYWVSh2yKyn3FVJCM1tLrtjdrtuo1J9RTJLTTbkE29xsb0JpBcxhJjg5pY59jbWOVNT3Wj3C5MLrIPY1nyWt7HnzIDx6UmgOW8aeFWl36jpS57yRD+Yrzi5BVisilHHUEYr22O6mgbBjfB6jFZet6Vp2pIWnt9kv94DFUvMbeh4vNioVHNdlq3h+2g3GJjjtXLXEXlTbe1aLRGUtx8AxVtKrRCrKdaxkzaC0J16UppFoaoZqhDURHNSUw9acSWPiODXa6U2+CI+oriU+9XYeHiXgjFaGbO104fKtTapeHaIoz9arxyC3tyx+8RxVMEyNuPU1ZFiSFNxxWtboEUcVVtIsckVe4C0kBFMyjqc/SqpO48dKmbByTUaLlqokmB2wH1rj76ZoNakdFDFuMH3rsr0BLUsPSuJ1Q41Zv91D+tQzRHJMfnY+9OU8VVneW0umiuUZOeCR1qZWB5BrFxsbwmpFlHxV2G4IABrNU1KjYrNxNYs1fNBFRsRVRZMU7zMjrSsU3oTJqV3ZMHtXwR0BrX07xfNdMI7tVWccZPeudkOc1mXikcqSCOhFdEJdGctWF9T08/wBo6gm2C78lT6VJZ+FoN3malcvcN15Nef8Ah3xTNYTpHdktFnGfSvUbKeDUbYS20qyAjoDW6ONomBtbGPZZwqCPQVnXXnXLFrhzt7KK0ViA7VTvAc47UE2Kluo+0RKBwWAroxLNYSArkr6Vg2vy3cLn7qsCa9EfR1vIgc4DDINIpbGdY6qwbfE5UnqtX2vbiXEhlJUds1kX3hu8sj51s3mKOoFP0yN7gkNuQj7wNNEs6/R7k3EMhP8ACQKv25wCPes3RohDAQP4jV+NsEjuDTGQa3YDUtOurcjJMeV+tecJaahpb5jRmVeor1aBsOT7VK1klwgkCAk9Rik0NHnmn+JhEQLhXQ966ew8RwOBsuB9Cau3Xh/TrgHzogre1ZM3gvTWO6O6Mf0qbFpnSQawsq8lGFLNFpt4pFxBGc+wrlf+EVjh/wBVqpA96li02WE4Goqw96Vii5feD9JusmHEbH3rmr/wFdR5azmBHpXRxxTL0ulY/wC9U4bUEHyujD2NKw0zzW88P6pa5EkG4DuBWXIl1bHPlupHtXrj3t4oxJbl/wAM1UnvIGH7+y5/3aVh3Z5gmqyLxKjEfSphfWU3Eg2n3ruZ/wCyJTh7Uj6LWfcaXoU3/LJ1z7UWC5yUlrby/NBKAT71VeC7hPHzD2NdVJ4f0jrHNJHSJotmhyupAD0NKwc1jll1K7g7yL+NTp4iu1/j3fWukNppMf8Ar7tH+lVZ5dAj/wBXC0jeoFOysCd2Y51+5k48lWPrtqndTXd0PnQKv0xWzJf22CLe12+mRWddzsylmwq0tB6o5TWIVRCW7cmvPL1/MumI6Z4rrvFeoF90UJ4PU1x0i4YZrRIzk7smi7VZWq0VWkrKRvAkBpTSCg1BrYSm0ppKaRLHL1rs/Ci/6OrHoDXGLXZeH226agHU5q0ZM6CaUzSYH3RxVu0iLEVUtI9xGa14MKMAVoyCzGm1aVz2o5xTGJ5oQXIpOmBRbjLc01uvNWLVc496GBBqbBYAuetcbqo/4moPrGv866fxBdRQ3AiZhuA5rl9RIkvEdemwVnfWxp0R6trHgLTtf05l8tVlx8rAcg14V4l8PX3hbUWtr1G8on5JMcGvpfw9fgTGNzwa0fFvhWy8VaRJbXKLvZfkkxyprRWmjGTcHdHyXG2QCKkFavijwjq3ha+khuLeSSBT8sijIIrDju4icZ2t6NWEqbR006qZYzS7jTc56c0hNRY1uPLVWuBlTUpNRSHimiZaoyLhOoq1out3mkXAktpCAOqnoaSdM5qjImDXRBnLOJ7NoHiq01a3Qu6xz4+ZSa3JIfNAZMMD6V8+RBkbcjFW9QcVs2WsapbqFjvZgvu1VczcbnrN5G8bLEo+eQ4FevaJETplusv31UK1eQ/DTR768nh1LVnkdAcorn9a9qs12yMo6EZFUibEU8RiY4GVNZV2kULl1QBj1xXUPGGiwwqpJbwLC73ABCjNMlszbDK2sZPUsTU4OJnH400yI0SNGMJ0H0pJeLhT2K0gehZhb5j9KuWt2YgB2FZsb4aprZg9u5z0kK0DN3EU6BgBk1C+mLL0qhaXXlPsf7p6VNqLXQhWWzfIHUCgakMn0Qc5zis640uFOSzAVLBrF5G2J0J+taMWo2lwuJowDSNEc5JDaw5+cmqr3kURO2Q8dOa6m4s7CdTtUDNY194ft2BMbVLQ3uZZ19owQGDYNNPiRh96JG+oqpe6LJHkpnrmseewuUJxmpsPobcniVDwbSPP0qvJ4jXH/Hug/AVz8lvcJ95TVeRJgOVNAI27nXEkGPJUfhWTc3UcueMGqEiSn+E1EYpCeallErtCfr7VH5kY6daZ5WPrT47RpD0wPWlZlXRFJdKOEGTWVqc0rod5wPSti4ENqmF+aSsDUmLJz1NUQ2cdrHLhR1JzWJcffFbGot5ly+OQOKx7viRfetFsZ9R0R5FWVqpEcVaU8VjJG8SYGgmmA0uag0QE02gmmmrRLZIh5Fdp4dH+hxZ964pOa7jQRiCMe1UjNnSW46VqQKAKzrYcitAOAKsjckdqYW4po+Y5oamO1hmNzCtWzQRo8z/cjXJqjbQmSRQBkmr2usLewW0T77cuf6VOm4bux5/qczXl9LKed7cfSqV+xiYRry2AtbkttFFukYYCjOa5G71aBLotgu2ePas4K7uXN2Vj2C4up9PK3C5wjZP0r0rw1qqXdrHIrZVgCK8x1K3vJoZIzGfmGM1P4Eur2w3Wt3G4RT8rEdqdOVhTVz2C+sbXUItt1CkinsRmuA8SfCLw/qyu9vGbeY906ZrtdMvRKgyetaYI6r1rdWaMGrHyv4p+FXiHQS8tlGby1HOV6gfSuDllaByl1G8UgOCGGK+6htkUhu/BBrl/EfgHQdcVjd2MJkP8YXBqHBPU0VSUT4+EocfKQRTWfivXvGHwSmtd8+gykgc+WTXkWq2F9pNwYNRt3icHGSODUezfQ0VW5Vc5zVeRc1KWBHFNbpTSsS3cgVea7H4a+G38Ra9GkgP2SE7pD6+1cmEJBOOK+jPgto62fhyOcriSY7ifaqWpD0O5trCOGFI4lCqgwAKtwPsZd3VatbMDgUyWAkbgKu1jK+poZDR5HSud8TXXl6TOQeW+UVp+eRae/SuT8TzGWKGAHOW5oJZftGP9kW5PXYKsyMTBE57cVCibbCNPRQKUEmyZe680dQJon+eodInYzX0LdFmLD8aZbvkA596LNdlxO+Pvtmgdy1du4HFSaXqbRSCNz8ppxUSR4NZF3E0LFhQNM6u4QSR+Yqg96y5TEpzsIxUek6oVQK5yKv3KJMnmRAEHqPSkWivHcIeBxTzKTx2rPdth6UecccfSkXcuTNuXGO1ZN5ETyq5IOasi5bHPripY5gScgcrikI5u4hlJwIz+VVjpd5J9yA/jXX/ao0+8q8VDca4kIO0DNFhnJ/8ACOak/WIAUHwtdDmXCitC/wDFMyg7OK5TU/Ed/cMQszKDS0GjRudOsbBS1xMN3pmsG+1OMkx2i8etZ8nnXL5ndmPvTkjVOAOam5ViNlJBZ+TWJrUgigkkPpgVvSgkVx3ie5EkiwIflHWnHcT2MI8qxPU81k3x+da2H4Q1i333hWhkEZqwhxVJGqeNqzaNostA0uaiU07NRYtMdmg03NOHNMCSIc13Gifdj9hXExV22icqv0pohnT23QVaHJqrbfdFXEIqySReBilC880gIq9p1v8AaHLtxEnU+tDAuabCLeE3Mo9kHqapXiNKzPIDlquCc32oCKMYgiHAp+p7YLZ5HwAozWM3f3TWC0ucZqTQgPDKcZ7V5x4isvI1JSgxG2CDXZSym7u3k7E5qxFp6XduI3VZJm5UEZxWsWoqzMpJyZ69yD0FSZLD5lXHsKjwQ3XineYqj5q51c1dixY3DW8u0n5TXVWF2JFAJFcU1xG7hV69q0bG6KNtJIIreLfUykjs+SODQl15bBJhx2NZ1ld7wOc1fZUnTB61omZ2LWxXG5cEGuf8TeEdK8Q2zRahaxvngMB8w/GrSyyWUu1yTH61pw3CSAEEGi4NHzV4z+CN/ZSPPoD+fD18tuory2/0LVNMmMd/ZTREHqVOK+7d3HFU7zSdO1BSt7aRSg+ootcSbWx8YeGfDt3rd/HbWkLNuPzNjgCvqPQtK/srTLW2A/1SBTj1rpbTw5pWnA/2bax25bqVFOlsmA+U5otYG7lSIBl5pzAdO1NKmB/n6UTspjyppkGNqMmJY4YzyzVh39k0V/CJDnc2RWpLmO+Ez8qp4qK4uY7rUIhxuXmgloll4jAFMUcsvquKmkOTgdM1HINrA0DRSs9yXBU/dq8E2klarjCyM3vV+Jd0O6gBiy7V296inIkUgikl6moGbjrQUip/qZOOlathebGAzwe1Zs3zjI602OTyxluD2pD1N+5hWdfMhxnqRWVKHjzuHep7S5YIDn3qxIVnXcMZ70DTMp36BeoH61XknlXHzd8VYmXazAdd36VXcg7sjou6gtEEszspHJOKy7xmjUs5q3dXHkqTWBctNeP3C1LZSKd3cvK5SMZqFbVjy9aa2ohT/aqtcyYGBUFXKpQLwKjKljhRUyI8hwO9QajOtsghjOZT1x2pDuUNUuhDEyIct3NcBcuZLlmPPNdFrU/lQPzmRuK5uNCRk1okZyGuMqax9RGNtbjKAOax9UHTFUQZ6mpVaogDUixse1JlJk6PUoNRpC2OlSiMjrUM0Qop603Bpy1JRPD96u20Jf3a/QVxMI+YV3mjLthT6CmiWb9vVtBVe3XgVpWVs1w4A4XuashktjaG4bn5UH3jUmp3yRxi2tsLGvGR3pdRvEtovIt+3U1ghjLLzzUydhxTOt8Mw/6NJM33mPFYfxBv9kMVlGcM53Pj0rqdOxbaanoFya8316Rr/XjnncfyWsoe87s1k7KyMW3dkvFi6Fhn8K1PBjPLroRyTw2Pyqrrdo0Gv2yjgugx9KveEGT/AIS2NY/ugMD9cVo9Yu5nFanpYm+zxKm8uV4zVaa7J78VFITk023tXuXzzsFUyLkltI0sy7euciuq+ym5t1ng4kH3h71z9pD5V5FgcZxXb6fB5bb1+4/UUWGZNrdPFJtk+VveuhsbwNgE80l3psU6/MvPZhWTJZ3Nk25SXjp2aJudQ6Jcx7W69qy3guLST5QStMsb4MoBzn0NbMFwsgAYg/WnuBWtb4HCycGryOG5BFNltIJRkjB9RVVrea2OUO+Oiwi9uI78UhcH2qGKZJBjOD6GiRfSncdrjZ1VlIYZHrWLduq5RDxWpKzbSprD1JkiyQcepNBDMzUbxUjaMDLYzXL2czf2jI8sgQg8EnFUvEvie2sZHWPM1xggAdBXn13qN5eO0k8rKfRTjFRKpGJdOhKoe8WxSZAVlRvoasSQtjgZr51j1HUrds2d/Kp924q1/wAJd4rt1wt6pX1xUqtFmrwklse7vEwJyp6U/T7gAvBJwe1eDR+O/EoYb7tCPTFb+jeO7iSVRqCgEfxirVSLMnQnHoetOPmK1VlXBIPaq+majFfRLLE4YEVbmG4Ve+xLVjNuJyvyQrk+tVQ7vJyScdauyJk7IxgdzWfdXCIxihHTqaTEXop8Dbu4qZLooeKyYnGOOtWRKpAGKQGnMVuI/MjI3jqKzLmYopx1PFM89oJd6HjuKkmZLmIyxdRyRQy0zKljeVsv0PamSReUvpU00jAnHUVnzmR2IJOKllohuJGOdpqBLcyNzVjy1Tlz71Q1DUSqmO2HJ4zSuOwaheJaqYoceYe/pXP3MvlhmJ3OepNSyHaC0h3NWRfTk5UdTSvcepjazMZG68Vn+cEUVPqeRhe/eqiwu+MA1aaS1Js5bDJrh24Aqq0DzEZrXisCeWq0loF6CsnWS2NYUG9zEh0zoWNXYrBFrS8rA6UhXArKVRs2VFIqeQo7VDLAvpV1zVeRqcZMHFFF48VERg1YkNQk81omZPQltRmZB6kV6Bpi/KoHQCuD05N93GPevR9BtzM6qOnrVxMpM29OtmmIA4Hc1pXdylpB5UXB7mklkSyg2r97Fc/dXJdiSeatuxNmxt1cFmPPJqXTxufP4VnZ3NzWppuFKhjgZ5NZvUtOxseJ9WXSdCQ5zJL8qiuc8IWkl9dNd3A5Y/kKzvFd4NW16G3iJaKIBVFeh+GdOFrYKWXBxWcvdQ17zOR8bwhPEOmuBwUNY/g1yvipM9d2PzrpfiGgj1fSG7EMP1rmdFHk+L1A6eYv86v7BO0j1BLdppQoHU1vRWghhCKOatadppjHmSD5j0q28BHIraxizGW0Z51Kjoc12GnLmFQazrWHapJHzGtTTf8AVEehoGXEGOKcUU8EDFCgGnYzQBn3WlxyHfD8re1Uj51q37wHA71vDIpJYxIpDgEGkMhsLxZkCseatsdvSsKezltZvMtz8n92tWynFzFzw46ihCYSwrKcr8r1CZJIjtlHHrU8yEetZ19eeTCdxBPvTC5Dql6ILaeYDPlqWx614L4r8bahqFw8Nt+7TOOK9Uv9TBLhz8mPm+lfN+q3rNql20fyr5rY+mamS0KpSXNsaDpfyZcYZz3J5rEv5tRgf97EwHtUsWoTI2RIa0I9TEwC3A3e9c/LZ3Z3891ZaHNvqkw4dWFT2esuDtf5lrcmS3mHKqR9KpSWFkH3Dg+goTj2CXN3HkrKgdOM1JCGzzTNyDCxcCpkPFZtWKTNrw/4gutGuVZSXtz95a9W0fX7XVoA1vIu/upPNeIhgDUtrczWU4mtXKOOwPBq4VWjOpQUtUe7Sy7UIHU96xbkBSSK5zRvGkU8axX3yyDv61uNf21zFmJwfxrpUlLY4pQlHcdBMN3HWrY55zWHJOEb5aniviVABo2YrXL8knO3qKpfbHs5tw5TuPamzTnHBFZN/dhV5YUpMEjo3ljkUyqflYVn3V0kY4IzXORayIFZC/yH9KrS6vDyTuJqXNG0YM1rm4eTPOBWfI4XrWZPqzvkKuBVKW5ll/iwKyc0aqnIs3t5yVWs4NzuxlqeE555qVQq9qn23YtYe+rZS+yCR98g5qwlui9FFTl0AqB7lVrNycjeMIwHbFHUU1ioqrLd56VXe5J70JCci1I45qtJKO1V5JyR1qu81UokOViaSSqkktRyTEnrUJfnmtEjGUx7Pmm5zUZanRgsRWiRm5GxoMJkuAQOlep6OFs7MMfvEVxPhayMcPmuOW6V1MkxCBe1XEyepNfXfmOWJrNZy54pHYs3PSpoQpxxTsNOwyNcsBVm9MkdjIYVy5GBinKgDjFdLo2l+ZsebG0nOKlj3MbwL4UleX7dfKR3Ga9GEQRQFHAqWJQsYjQYQdqHICmuabubRjY86+J423GlP6MRXJae3/FXQH+9Kv8AOuz+JAEp09R94Pu/CuE098+LbQDtMufzroXwGT+I+oAuabKu1CVGSKVDk0soJQ7etbGBDbOHHPDVcsztkZRXPLPJZ33737jHFblvJ+/DDoRQUjTU1KOlVmPGaWKUNwTzQItAZqQLxTF6U+iwEUigjB6VWMWxt8XDDqKsT3MEK/vHGfSqf2pGOU6UCuWvtSPH82AR1riddvxJcOAwCiunkaJslu/WsPULLTZGO4HJppGc5PY4XX7yKzsJ7mR8oo7d68E1C5We8ml2lFdiRXuvxL00SeHZ1sASYiHI9RXhDujjawx7Gs5s0oxRXaTBypBFTQ3KA/PxVSaPacxmocN/FUaHRdpm9HOjD5WpWZMcsKwAWU8E0olbPJNJwW5ftGbquoPBqwkoIrAjnIqxHc+9ZuBpGobW8Gl3Vlpc5qdZ/Q1m4mqkXOD1HNTwXc8H+qkI9s1nCbnmhp/Smk1sJ2e5vJrF2Rh5BT/7WuF6SAe9c59o55o8+q5pEqMDcm1O6fjz2/CqbXErH5pmP1NZ3n+9NaY0m5MEorY0GmwMk5NR/aR3rPeRj3phc0uW4+expfawKPtfoKyi+KTzSKrkF7Q1/thprXnvWQZ6aZqXIP2ppvdk96ge4z3rPaYmozIfWqUCHULzT1G03vVQvTC2apRIdQsPPnvULSE1GaMVXKZuTAsaXmlC5p8UZkbagJPtTSJuNVSetbehaW91MGcYjFWdI0KR8SXPyoO1dRAIrdBHEvA71VhXuWYI1hjVRwAOKSSSoGkJPWpYI/NPJ4o2Cwi5Y1dhiIXJFTQi0gHzNub0qdBJcti3gcj6UwF0+HzrtAelddavtmVE7VmaXpNyh8yRBGMdTWtFJbWp2798zHHFJ7At7G2jfKPpTXKnqaYjYUZ9Ky9fvRZWEkpOCRhfrXLa8jpvZHGeJ71LrVpmP+ptkKj3Nc94LsJL7XTeMuI42LA+9S6kzPbeUv8ArJm5ru/CGlLZ6WgK4ZhXRO0Y2MI6yuelwvkirgG4YrBsnvFUfaYgrD0rUt7gZw3H1rexiyLUbQTREEc9jVWxuCiiN/vpxW5tDj1rD1izcfvYMiRf1pMEb9vKJUxVe5jkQllNc9puseXIEn+V66eK8jmiByDmkhjrS7Jiy5+YdahvNTc5WPgVIkSsSegNNkSwHys/zegq0ZSl0Mrczybn5+tSNL5fA6VeNmkn+q5HbNVpbG4BwsefxoJK5u+uRwKrXF5ahCz4Bq41hPtIeMAH3qg+i2xYtcu2PTNNBqc7eSG5hnKr8j/KM+lfPfiGFI9VuVjG0ByMV9PXNvaouITkDoK8C+JujfYtXe6gOYJzkj+61RIqD11OIzzinqoI5FVyxBINAkZaysdKlqPkjx0FVyOaka6zwRUZbdzSsym0wHFOBNIKUCmTcernNTCUiq9OFS0WpFgTHvR5h9ago5pWHzFgSe9G+oKUA0WDmJw59aUScVD2ppkUHll/OiwcxYL+9Rs/vUJlX++v50hdT/Gv50JA5km400k0gwehBpeB1qrE8whpDT9ygU0yJ60WFzDCDTcGnGVaTeD0p2JbAKaNtPVZG4VKnispn+9gUWC5VwKkSJ5DhFJrTt9NQEGQk1q20EcYG1aBbmVZ6O0uDK20VvWdvbWagRR7n9TTlAJxVy2h3EccUXSCwivLKcAYHpU8VpK567RV2GHA4FW40wBmhMLEVjo4kcb5Ca6nTdAsgAZtx/GqmnRgYJrTlvVhiwvWqsFrF1rfSrJeLaNiO7DJqlca0EGy0hjQewrKnuHmJZzxVZnwDt5oHYuXGoXExw8zAegNXdBi8263sMqozz61j20Ek75YYFdbpEAhhIA5rOpdLQuNjRZu/auD8Xah9r1EQKf3MAy/1rq9Vujb2Ur9wML9a8w1GYvIIUOZZWy5qKUeo5y6Gh4dtW1HVBKw/dqePpXpsAVAqjhQOK5vwrYi0sw2OSK6BWzUzd2OEbI2riacrlWPFJYXhd/Lm6nvTkcPFVB8pOMetdlzmOlt5miYLJyp6GtBlSVM8Gse3lDxgNg8VKszW/O75PftTEypqmipOS6DDetVLY/2cpEzl8dAOasTaw13MLe2YBScFvWr9pZwwgMw3v6tRZE37Gcb2+vBtt4XRPUilXSb1vmMoVj6mt3ztq4XA/CoJHLd+aoh67mBd6ZqyKTBqGCOwNZY1DVImMV1NIrDo1dilqZT1NTNpsMi7ZVDD3ouxcpydtc3Z+Z74ye2auLNI/Dn86vXPh6w3bt7xN/stVc6VZKOLqRj6E0XGjMuoSj7xKoHcZrzb4jwC5hZo13hRk4r0288NR3b7mnZYx6Gs+68P6bHGVSV2OOd3NTa4any7Pt3HBGe9RmvS/HXgeFWkudOYq/Ur2NeXMXgkaOYFWBxzUOJtCaejJCgNKEFKpBFOH6VLNUN24pcU6lFQMRV5qRVphkRfvHFTW0c924SzhaRj3xxT1AaVA64AqNpoUOC2fpXZ6L4ClvGVtVnMYP8EfWvQtF8AeGLBVkuITM4/wCehzQokuolseGQrNcnFtazSZ/uqTW7pvgvxNqZH2XT5FU92GK+h7A2tqoj0uxjRR6JWvC+pzYCRhF9lxVKHcj2p4bpvwW1y5AN7dRQg9RnpXUWHwL00IDfXju/faa9ZitpU+e8lwB2zUN5q1vApWL5jVKNiXNs81l+BugKM/apgP8AerJ1D4QeH7dTsupy3+9XfX2qSSsdz7R6CsuWUSH7xaq0JueLeKPBTaGRLbTGSAnHPaufazIHzEgV7Z4qsftGlqgGcuD+VUfDPglb+cS3Snyh2qWNM8eFlI4z5T7fXFUZ4zFLtdSo7ZFfVB8K6eIxGIEAHtWTqngHTLuIpJEMH26UWKbPnKGNWI71eiiUdhXd678LntXY2Fw2eqg964bypraaS3uRtlibawpiTLMSgdKsxjPWqiNxU6NUll2Pb3qymO1UEcZ5q1E4J4NK40y7EoJrQhZVAwKoQDOK0YYiQMAmla4XLcV1xgLVi33SyD0qrHFLuAETH3xW1YWcvGI2z9KaHsW4vkQAU9YTPlD1PStC00ueQDKGta10NsgtxVE3OdTw/cy8+YMelW7fw1Ln5iPzrpPIEA5bpVS4vVjzh+aAI4dIjtlyzAmnIwV2VTWdcaluJ+aoPtot7K5uXOFQE1EtdCo6amJ421gLN9ljbhOW+tc/4ZtjfX/nOMgniudur6XVdQfB/wBY+fwr07wlYLbWiuRzjAqZPljYpe87m/CmxFVRgAVKOD70oRm+6OKrXOoabYnN7eRxn0zXOk5G+iOitP8AVVXm5nWiivQOJGhB936Vma1PJhYw5CtwcUUUCY7TI1S+iVRgAZ/GungOQc0UUyCUqDTo41YgmiimJF1VCgYqteyMifKcUUUCZzV3LI7ncxptqoaRQSeTRRUiR0cSKEUY4qU6baS4Lwqc0UUxmHrmjWBiYG3WvBPib4d05d00cRjkHdTiiipYzy+CMD5ckgVbEK7epooqGdECGZdowCRUBBH8bUUUJIUnqW9MtY5p183c31Neg6TDHbxoIVCZ9KKKGQzttLGyAuOW9TXV+GrKG7YNcBnJ9TRRTiQdrFawwIBFGoA9qq3t3LEpCEL9BRRVAjn7u7nmJEkhIrHvnZVODRRQwM1I/Of52b86uw26L0B/GiikgLht45QodcgHit/TYUjgwgwMUUVYLcWT71IecZooqSmUb6JHZAwzg5r57+IMSJ4wvAowCcnFFFMmO5jLGPU1KkY9WooqGalmK3Vupb860bW2jGOtFFSM2bSBB2rYso13gYooqkB02nxoEB2j8q1VfywNgUfhRRQCI5dRuI/uMB+FZ8+tX3/PX9KKKBlVtQuZR88pNRl2ZTkk0UUxkO0Hrms3xdK8Xhh1Q4DzYP0xRRUsDifC0KG5BOSc17RpaKtsmB0FFFYy3NImD4v1i8t7WRIHEYx/CK8iuFa8mMlzNK7E92oorWCIqM//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD &copy; Scott Sherman. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13632=[""].join("\n");
var outline_f13_20_13632=null;
var title_f13_20_13633="CT perimesencephalic nonaneurysmal SAH";
var content_f13_20_13633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perimesencephalic subarachnoid hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan demonstrates the typical findings of a nonaneurysmal perimesencephalic subarachnoid hemorrhage. Note the predominance of hemorrhage in the interpeduncular fossa (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Guy Rordorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13633=[""].join("\n");
var outline_f13_20_13633=null;
var title_f13_20_13634="Dobutamine stress CMR predicts lack of viable myocardium";
var content_f13_20_13634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68495&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dobutamine stress CMR predicts lack of viable myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 202px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dobutamine stress CMR studies in a patient with three vessel disease and a prior anterior wall myocardial infarction.",
"    <br>",
"     (Left upper panel) At rest, the short axis CMR during diastole shows that the diastolic wall thickness (DWT) of the anteroseptal wall is significantly reduced (arrows).",
"     <br>",
"      (Left lower panel) The entire region shows a lack of systolic wall thickening (SWT).",
"      <br>",
"       (Middle lower panel) During a dobutamine infusion, there was no measurable increase in SWT of the anteroseptal wall, indicating scar tissue.",
"       <br>",
"        (Right upper and lower panel) Six months after successful bypass surgery (CABG), the reduction in DWT persisted (arrows, upper panel) there was no improvement in SWT.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reprinted with permission from: The American College of Cardiology (Journal of the American College of Cardiology 1998; 31:1040).",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.elsevier.com/locate/jacc\">",
"          file://www.elsevier.com/locate/jacc",
"         </a>",
"         <br/>",
"         <a href=\" file://www.sciencedirect.com\">",
"          file://www.sciencedirect.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13634=[""].join("\n");
var outline_f13_20_13634=null;
var title_f13_20_13635="Candidiasis vulva2";
var content_f13_20_13635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidiasis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13635=[""].join("\n");
var outline_f13_20_13635=null;
var title_f13_20_13636="Delavirdine: Patient drug information";
var content_f13_20_13636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Delavirdine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     see \"Delavirdine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rescriptor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rescriptor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to delavirdine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids or didanosine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may put tablet in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       glass of water, let it sit for a few minutes, mix and drink. Rinse glass with more water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12356 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-7C4F869326-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13636=[""].join("\n");
var outline_f13_20_13636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157366\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157367\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018873\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018875\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018874\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018879\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018880\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018882\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018877\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018878\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018883\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018884\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=related_link\">",
"      Delavirdine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13637="Dextromethorphan, chlorpheniramine, phenylephrine, and guaifenesin: Patient drug information";
var content_f13_20_13637=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"23\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dextromethorphan, chlorpheniramine, phenylephrine, and guaifenesin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4303183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chlordex GP [DSC];",
"     </li>",
"     <li>",
"      Donatussin;",
"     </li>",
"     <li>",
"      Quartuss&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextromethorphan, chlorpheniramine, phenylephrine, guaifenesin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Enlarged prostate gland, high blood pressure, or overactive thyroid gland.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12388 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7ADB670DEC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13637=[""].join("\n");
var outline_f13_20_13637=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018969\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018971\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018970\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018975\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018976\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018978\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018973\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018974\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018979\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018980\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13638="Levothyroxine: Patient drug information";
var content_f13_20_13638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levothyroxine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     see \"Levothyroxine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"     see \"Levothyroxine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F188360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levothroid&reg;;",
"     </li>",
"     <li>",
"      Levoxyl&reg;;",
"     </li>",
"     <li>",
"      Synthroid&reg;;",
"     </li>",
"     <li>",
"      Tirosint&reg;;",
"     </li>",
"     <li>",
"      Unithroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eltroxin&reg;;",
"     </li>",
"     <li>",
"      Euthyrox;",
"     </li>",
"     <li>",
"      Levothyroxine Sodium;",
"     </li>",
"     <li>",
"      Synthroid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10012317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700809",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat obesity or for weight loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add thyroid hormone to the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702387",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levothyroxine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Overactive thyroid gland, recent heart attack, or weak adrenal gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is more than one brand of this drug. One brand cannot safely be used for the other. Your doctor will tell you about any needed change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron products, antacids that have aluminum and magnesium, calcium carbonate, simethicone, sucralfate, Kayexalate&reg;, colestipol, or cholestyramine within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling more or less hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A change in weight without trying.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bothered by heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698178",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Grouchy or touchy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach 30 minutes before breakfast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush tablet and mix with 1 or 2 teaspoons (5 or 10 mL) of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10807 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13638=[""].join("\n");
var outline_f13_20_13638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188360\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188361\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012317\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012319\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012318\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012323\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012324\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012326\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012321\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012322\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012327\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012328\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=related_link\">",
"      Levothyroxine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=related_link\">",
"      Levothyroxine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13639="Treatment of severe hypovolemia or hypovolemic shock in adults";
var content_f13_20_13639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of severe hypovolemia or hypovolemic shock in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13639/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/20/13639/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid volume repletion is indicated in patients with severe hypovolemia (ie, decreased peripheral perfusion, as indicated by delayed capillary refill and cool mottled extremities) or hypovolemic shock (ie, severe hypovolemia plus hypotension). Delayed therapy can lead to ischemic injury and possibly to irreversible shock and multiorgan system failure. Three issues generally need to be considered in this setting: the rate of fluid replacement; the type of fluid infused; and the role for buffer therapy in patients with concurrent lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/1\">",
"     1",
"    </a>",
"    ]. Vasopressors (eg, norepinephrine) generally should not be administered, since they do not correct the primary problem and tend to further reduce tissue perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATE OF FLUID REPLETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not possible to precisely predict the total fluid deficit in a given patient with hypovolemic shock, particularly if fluid loss continues (eg, persistent bleeding or third space sequestration). In general, at least one to two liters of isotonic saline are initially given as rapidly as possible in an attempt to restore tissue perfusion.",
"   </p>",
"   <p>",
"    Early correction of the volume deficit is essential in hypovolemic shock to prevent the decline in tissue perfusion from becoming irreversible. Irreversible shock is associated with loss of vascular tone, a drop in systemic vascular resistance, pooling of blood in the capillaries and tissues, and an impaired response to vasoactive medications.",
"   </p>",
"   <p>",
"    Fluid repletion should continue at the initial rapid rate as long as the systemic blood pressure remains low. Clinical signs, including blood pressure, urine output, mental status, and peripheral perfusion, are often adequate to guide resuscitation. The development of peripheral edema is often due to acute dilutional hypoalbuminemia and should not be used as a marker for adequate fluid resuscitation or fluid overload.",
"   </p>",
"   <p>",
"    A central venous catheter should be considered in patients who fail to respond promptly to initial fluid resuscitation. In such patients, monitoring the central venous pressure can help direct therapy. There is little added value from measurement of the pulmonary capillary wedge pressure, unless the patient has underlying cardiopulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient does not respond promptly and central venous pressure monitoring is not available or cannot be performed, some data suggest that respiratory variation in the arterial pressure tracing can be used to estimate the adequacy of fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Large respirophasic variations in the arterial systolic pressure and pulse pressure are qualitatively linked to persistent hypovolemia and right ventricular underfilling [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/4,6,8\">",
"     4,6,8",
"    </a>",
"    ]. Respirophasic pulse pressure variation provides information about the likelihood that the cardiac output will increase in response to an increase in left ventricular preload; it does not provide an absolute assessment of volume status [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The use of pulse pressure variation to assess volume responsiveness is only valid in mechanically ventilated patients and is unreliable at predicting the volume responsiveness of spontaneously breathing patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DELAYED FLUID RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different therapeutic approach that emphasizes limiting fluid resuscitation and allowing a mild degree of hypotension until hemorrhage can be controlled may be beneficial in patients with hypovolemic shock due to gunshot injuries, stab wounds, and head injuries. This approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHOICE OF REPLACEMENT FLUID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of replacement fluid depends in part upon the type of fluid that has been lost [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/1\">",
"     1",
"    </a>",
"    ]. As an obvious example, blood components are indicated in patients who are bleeding. In this situation, the hematocrit should not be raised above 35 percent because a further increase is not necessary for oxygen transport and may increase blood viscosity, potentially leading to stasis in the already compromised capillary circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Colloid versus crystalloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both isotonic saline solutions and colloid-containing solutions have been used to replace the extracellular fluid deficit. Some clinicians advocate the administration of a colloid-containing solution (eg, albumin, hydroxyethyl starch [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"     hetastarch",
"    </a>",
"    ]) because of two possible advantages over fluid repletion with an isotonic saline solution: (1) more rapid plasma volume expansion, since the colloid solution remains in the vascular space (in contrast to saline, two-thirds of which enters the interstitium), and (2) lesser risk of pulmonary edema, since dilutional hypoalbuminemia will not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, randomized trials and meta-analyses have failed to demonstrate either of these theoretical benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/13-23\">",
"     13-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A well-executed multicenter trial randomly assigned nearly 7000 hypovolemic medical and surgical ICU patients to fluid resuscitation using either 4 percent albumin or normal saline [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/13\">",
"       13",
"      </a>",
"      ]. All-cause mortality at 28 days (the primary end point of the study), multiorgan failure, the duration of hospitalization, and effect upon systemic pH were similar in both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/24\">",
"       24",
"      </a>",
"      ]. No differences were observed in subgroup analyses of patients with and without sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/25\">",
"       25",
"      </a>",
"      ]. However, in patients with head trauma, resuscitation with albumin was associated with higher mortality than resuscitation with saline [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 55 studies, published before the above trial, pooled and analyzed data from nearly 3000 critically ill patients randomly assigned to treatment with albumin or crystalloid [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/20\">",
"       20",
"      </a>",
"      ]. There was no evidence for either improved outcomes or increased mortality in patients given albumin. Subset analysis identified no group of patients, including those with trauma, burns, hypoalbuminemia, or ascites, that derived statistically significant benefit or harm from albumin transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Colloid-containing solutions are not more effective in preserving pulmonary function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/13,15,16,18\">",
"     13,15,16,18",
"    </a>",
"    ]. This lack of protection is due, at least in part, to the relatively high permeability of the alveolar capillaries to albumin, leading to a higher interstitial oncotic pressure than in subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/27\">",
"     27",
"    </a>",
"    ]. As hypoalbuminemia occurs, there is a parallel reduction in alveolar interstitial protein concentration, since less albumin moves across the capillary wall. The net effect is little or no change in the transcapillary oncotic pressure gradient and, therefore, little tendency to the development of pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In comparison, acute saline-induced hypoalbuminemia can lead to peripheral edema, which is a cosmetic but not life-threatening problem [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern has been raised about risks associated with the use of hyperoncotic starch solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Highly substituted starch solutions have been associated with coagulopathy, while hyperoncotic starch solutions have been associated with increased risk of acute kidney injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The lack of benefit and potential adverse effects of starch solutions are illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 31 trials (10,290 patients) compared the use of hydroxyethyl starch with crystalloids, albumin, or gelatin for volume expansion and found an increased risk of mortality associated with hydroxyethyl starch (RR, 1.09, 95% CI 1.02-1.17) and an increased risk of renal failure (RR 1.27, 95% CI 1.09-1.47) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/37\">",
"       37",
"      </a>",
"      ]. This analysis excluded seven trials that had been retracted due to concerns about scientific misconduct.",
"     </li>",
"     <li>",
"      In a randomized trial, 7000 ICU patients were randomly assigned to receive 6 percent hydroxyethyl starch or isotonic saline for all fluid resuscitation until ICU discharge, death, or 90 days after randomization [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/33\">",
"       33",
"      </a>",
"      ]. No difference was found in the risk of death at 90 days (relative risk with hydroxyethyl starch versus saline 1.06, 95% CI 0.96-1.18). However, more patients in the hydroxyethyl starch group required renal replacement therapy.",
"     </li>",
"     <li>",
"      When volume expansion with hydroxyethyl starch was compared with Ringer&rsquo;s lactate in patients with severe sepsis and septic shock (6S trial), patients receiving hydroxyethyl starch had a higher mortality and a greater likelihood of needing renal replacement therapy. This trial is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Intravenous fluids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Saline solutions are equally effective as colloid in expanding the plasma volume, although 1.5 to 3 times as much saline must be given because of its extravascular distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/13,15,38-40\">",
"     13,15,38-40",
"    </a>",
"    ]. This is not necessarily deleterious, however, since fluid loss also leads to an interstitial fluid deficit that is repaired by saline administration.",
"   </p>",
"   <p>",
"    In summary, saline solutions are generally preferred for the management of patients with severe volume depletion not due to bleeding. Saline solutions seem to be as effective as colloid-containing solutions, and are much less expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/13,14,17,41\">",
"     13,14,17,41",
"    </a>",
"    ]. Hyperoncotic starch solutions should be avoided as they increase the risk of acute kidney injury and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/32,42\">",
"     32,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood substitutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acellular, oxygen carrying resuscitation fluids may improve outcomes from hemorrhagic shock when blood transfusion is not immediately available. This is supported by animal data that indicates that the outcome of hemorrhagic shock correlates with tissue hypoxia. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=see_link\">",
"     \"Oxygen carriers as alternatives to red cell transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Buffer therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large volume resuscitation using isotonic saline may be associated with the development of hyperchloremic metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. This has led to suggestions that physiologically-buffered fluids (eg, lactated-Ringers solution or 0.45% saline solution with 75",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ) be used instead of isotonic saline for large volume resuscitation. However, a benefit from this approach has not been demonstrated.",
"   </p>",
"   <p>",
"    Patients with marked hypoperfusion may develop lactic acidosis, leading to a reduction in extracellular pH below 7.10.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    has been added to the replacement fluid in this setting, in an attempt to correct both the acidemia and the volume deficit. However, the efficacy of such alkali therapy in lactic acidosis is uncertain and its use remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"     \"Bicarbonate therapy in lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal monitoring of acid-base status may require measurement of mixed venous as well as arterial blood gases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=see_link\">",
"     \"Venous blood gases and other alternatives to arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10406742\">",
"    <span class=\"h2\">",
"     Chloride-restrictive fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the solutions used for fluid resuscitation in critically-ill patients are hyperchloremic (eg, isotonic saline, 4 percent albumin in saline) relative to plasma. It has been hypothesized that increased chloride concentration leads to renal vasoconstriction and decreased glomerular filtration, raising the possibility that the chloride concentration of intravenous fluids might adversely affect renal outcomes in ICU patients. In a prospective, open-label, observational study, the use of chloride-restrictive intravenous fluids (eg, lactated Hartmann solution, Plasma-Lyte 148, chloride-poor albumin) was compared with standard intravenous fluids (eg, isotonic saline) in consecutive ICU patients treated during two separate six month periods separated by a six-month hiatus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/46\">",
"     46",
"    </a>",
"    ]. The mean serum creatinine increases during the control and chloride-restrictive periods were 22.6",
"    <span class=\"nowrap\">",
"     &mu;mol/L",
"    </span>",
"    (95% CI, 17.5-27.7) and 14.8",
"    <span class=\"nowrap\">",
"     &mu;mol/L",
"    </span>",
"    (95% CI, 9.8-19.9), respectively. The need for renal replacement therapy was also less among patients treated with chloride-restrictive fluids. Due to the nonrandomized design of the study and other methodologic problems, further studies are needed before a change in practice to use of chloride-restrictive intravenous fluids can be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13639/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No benefit has been demonstrated for the routine use of lactated Ringers solution for fluid resuscitation compared with isotonic saline, as noted above. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Buffer therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       \"Patient information: Dehydration (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid volume repletion is indicated in patients with severe hypovolemia or hypovolemic shock. Delayed therapy can lead to ischemic injury and possibly to irreversible shock and multiorgan system failure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At least one to two liters of isotonic saline are initially given as rapidly as possible in an attempt to restore tissue perfusion. Early correction of the volume deficit is essential in hypovolemic shock to prevent the decline in tissue perfusion from becoming irreversible. Fluid repletion continues at the initial rapid rate as long as the systemic blood pressure remains low. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rate of fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical signs, including blood pressure, urine output, mental status, and peripheral perfusion, are often adequate to guide resuscitation. A central venous catheter is often placed in patients who fail to respond promptly to initial fluid resuscitation. If central venous pressure monitoring is not available or cannot be performed, respiratory variation in the arterial pressure tracing can be used to estimate the adequacy of fluid resuscitation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rate of fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe non-hemorrhagic hypovolemia or non-hemorrhagic hypovolemic shock:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend initial fluid replacement with an isotonic crystalloid solution rather than a hyperoncotic starch solution (eg, hydroxyethyl starch [",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/13/9430?source=see_link\">",
"       Hetastarch",
"      </a>",
"      ]) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Colloid versus crystalloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initial fluid replacement with an isotonic crystalloid solution rather than an albumin-containing solution (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Colloid versus crystalloid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe hemorrhagic hypovolemia or hemorrhagic shock, red blood cell transfusions are an appropriate choice for initial volume resuscitation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Choice of replacement fluid'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link\">",
"       \"Use of blood products in the critically ill\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large volume resuscitation using isotonic saline may be associated with the development of hyperchloremic metabolic acidosis. This has led to suggestions that physiologically-buffered fluids (eg, lactated-Ringers solution or 0.45% saline solution with 75",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      ) be used instead of isotonic saline for large volume resuscitation. However, a benefit from this approach has not been demonstrated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Buffer therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with marked hypoperfusion due to hypovolemia may develop lactic acidosis. The efficacy of alkali therapy (eg, intravenous bicarbonate) in this situation is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=see_link\">",
"       \"Bicarbonate therapy in lactic acidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.439-443.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/2\">",
"      Nordin AJ, M&auml;kisalo H, H&ouml;ckerstedt KA. Failure of dobutamine to improve liver oxygenation during resuscitation with a crystalloid solution after experimental haemorrhagic shock. Eur J Surg 1996; 162:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/3\">",
"      Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest 2002; 121:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/4\">",
"      Gunn SR, Pinsky MR. Implications of arterial pressure variation in patients in the intensive care unit. Curr Opin Crit Care 2001; 7:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/5\">",
"      Bendjelid K, Romand JA. Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care. Intensive Care Med 2003; 29:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/6\">",
"      Magder S. Clinical usefulness of respiratory variations in arterial pressure. Am J Respir Crit Care Med 2004; 169:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/7\">",
"      Kramer A, Zygun D, Hawes H, et al. Pulse pressure variation predicts fluid responsiveness following coronary artery bypass surgery. Chest 2004; 126:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/8\">",
"      Pinsky MR, Teboul JL. Assessment of indices of preload and volume responsiveness. Curr Opin Crit Care 2005; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/9\">",
"      Soubrier S, Saulnier F, Hubert H, et al. Can dynamic indicators help the prediction of fluid responsiveness in spontaneously breathing critically ill patients? Intensive Care Med 2007; 33:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/10\">",
"      Monnet X, Rienzo M, Osman D, et al. Passive leg raising predicts fluid responsiveness in the critically ill. Crit Care Med 2006; 34:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/11\">",
"      Teboul JL, Monnet X. Prediction of volume responsiveness in critically ill patients with spontaneous breathing activity. Curr Opin Crit Care 2008; 14:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/12\">",
"      Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983; 11:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/13\">",
"      Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/14\">",
"      Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998; 316:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/15\">",
"      Virgilio RW, Rice CL, Smith DE, et al. Crystalloid vs. colloid resuscitation: is one better? A randomized clinical study. Surgery 1979; 85:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/16\">",
"      Weaver DW, Ledgerwood AM, Lucas CE, et al. Pulmonary effects of albumin resuscitation for severe hypovolemic shock. Arch Surg 1978; 113:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/17\">",
"      Erstad BL, Gales BJ, Rappaport WD. The use of albumin in clinical practice. Arch Intern Med 1991; 151:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/18\">",
"      Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/19\">",
"      Bunn F, Alderson P, Hawkins V. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev 2001; :CD001319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/20\">",
"      Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/21\">",
"      Roberts I, Blackhall K, Alderson P, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011; :CD001208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/22\">",
"      Albumin Reviewers (Alderson P, Bunn F, Li Wan Po A, Li L, Blackhall K, Roberts I, Schierhout G). Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011; :CD001208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/23\">",
"      Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 2:CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/24\">",
"      Bellomo R, Morimatsu H, French C, et al. The effects of saline or albumin resuscitation on acid-base status and serum electrolytes. Crit Care Med 2006; 34:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/25\">",
"      SAFE Study Investigators, Finfer S, McEvoy S, et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/26\">",
"      SAFE Study Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australian Red Cross Blood Service, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med 2007; 357:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/27\">",
"      Taylor AE. Capillary fluid filtration. Starling forces and lymph flow. Circ Res 1981; 49:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/28\">",
"      Gallagher TJ, Banner MJ, Barnes PA. Large volume crystalloid resuscitation does not increase extravascular lung water. Anesth Analg 1985; 64:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/29\">",
"      Zarins CK, Rice CL, Peters RM, Virgilio RW. Lymph and pulmonary response to isobaric reduction in plasma oncotic pressure in baboons. Circ Res 1978; 43:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/30\">",
"      Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/31\">",
"      Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. BMC Emerg Med 2008; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/32\">",
"      Wiedermann CJ, Dunzendorfer S, Gaioni LU, et al. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010; 14:R191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/33\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/34\">",
"      Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2012; 6:CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/35\">",
"      Schramko A, Suojaranta-Ylinen R, Kuitunen A, et al. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth 2010; 104:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/36\">",
"      Wiedermann CJ. Hydroxyethyl starch--can the safety problems be ignored? Wien Klin Wochenschr 2004; 116:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/37\">",
"      Zarychanski R, Abou-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013; 309:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/38\">",
"      Riddez L, Hahn RG, Brismar B, et al. Central and regional hemodynamics during acute hypovolemia and volume substitution in volunteers. Crit Care Med 1997; 25:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/39\">",
"      McIlroy DR, Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. Anesth Analg 2003; 96:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/40\">",
"      Drobin D, Hahn RG. Volume kinetics of Ringer's solution in hypovolemic volunteers. Anesthesiology 1999; 90:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/41\">",
"      Alderson P, Schierhout G, Roberts I, Bunn F. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2000; :CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/42\">",
"      Reinhart K, Perner A, Sprung CL, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med 2012; 38:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/43\">",
"      Morgan TJ. The meaning of acid-base abnormalities in the intensive care unit: part III -- effects of fluid administration. Crit Care 2005; 9:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/44\">",
"      O'Dell E, Tibby SM, Durward A, Murdoch IA. Hyperchloremia is the dominant cause of metabolic acidosis in the postresuscitation phase of pediatric meningococcal sepsis. Crit Care Med 2007; 35:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/45\">",
"      Gheorghe C, Dadu R, Blot C, et al. Hyperchloremic metabolic acidosis following resuscitation of shock. Chest 2010; 138:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/46\">",
"      Yunos NM, Bellomo R, Hegarty C, et al. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13639/abstract/47\">",
"      Waikar SS, Winkelmayer WC. Saving the kidneys by sparing intravenous chloride? JAMA 2012; 308:1583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1607 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13639=[""].join("\n");
var outline_f13_20_13639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATE OF FLUID REPLETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DELAYED FLUID RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHOICE OF REPLACEMENT FLUID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Colloid versus crystalloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood substitutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Buffer therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10406742\">",
"      Chloride-restrictive fluids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40646?source=related_link\">",
"      Bicarbonate therapy in lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24073?source=related_link\">",
"      Oxygen carriers as alternatives to red cell transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/35/13877?source=related_link\">",
"      Venous blood gases and other alternatives to arterial blood gases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13640="Diagnosis and differential diagnosis of ankylosing spondylitis in adults";
var content_f13_20_13640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13640/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13640/contributors\">",
"     David T Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13640/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13640/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13640/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/20/13640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton manifested by back pain and progressive stiffness of the spine. It characteristically affects young adults with a peak age of onset between 20 and 30 years. The name for the disorder is derived from the Greek roots &ldquo;ankylos,&rdquo; which means bent or crooked, and &ldquo;spondylos,&rdquo; a spinal vertebra. Ankylosis refers to a fibrous or bony bridging of joints. In the spine, this includes bridging of one or more intervertebral discs. Spondylitis refers to the inflammation of the spine. The more general term &ldquo;axial spondyloarthritis&rdquo; may also be appropriate to use, as most patients with this disease do not have ankylosis of the spine.",
"   </p>",
"   <p>",
"    AS is a form of spondyloarthritis (SpA, formerly spondyloarthritides or spondyloarthropathies), a group of disorders that share a predilection to cause inflammation around the enthesis (the site of ligament insertion into bone) and an association with the human leukocyte antigen (HLA)-B27. Other diseases in the spondyloarthritis family are undifferentiated spondyloarthritis, reactive arthritis, psoriatic arthritis, juvenile spondyloarthritis, and the arthropathy associated with inflammatory bowel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and differential diagnosis of AS will be reviewed here. The clinical manifestations, treatment, and pathogenesis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no formal diagnostic criteria for AS, but there are several sets of classification criteria that identify the features that are important in making the diagnosis. These criteria sets were developed by cross-sectional studies primarily to identify patients for research purposes. They are useful in practice because they contain lists of SpA features that should be assessed in a patient undergoing evaluation for AS or another SpA and because they reflect the relative strength of each parameter. The SpA parameters to be evaluated depend, in part, upon the stage of the disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For classical AS, the classification criteria that are useful diagnostically are the 1984 modified New York criteria, which combine back pain with limitation of range of motion and radiological sacroiliitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H33#H33\">",
"       \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Modified New York classification criteria for ankylosing spondylitis'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H32243117\">",
"       'Modified New York criteria'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For all axial spondyloarthritis (axial SpA), including those without sacroiliitis on plain radiographs, the diagnostically more useful criteria are the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial SpA [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with axial spondyloarthritis but with normal plain radiographs of the sacroiliac joints are defined as having non-radiographic axial SpA (nr-axSpA). (See",
"      <a class=\"local\" href=\"#H9478399\">",
"       'ASAS classification criteria for axial SpA'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria do not provide a method for estimating the likelihood of disease based upon each individual parameter. However, a 2004 algorithm for diagnosis and referral has been developed that allows an estimate of disease likelihood based upon the patient&rsquo;s history and findings (",
"    <a class=\"graphic graphic_algorithm graphicRef80964 graphicRef59693 \" href=\"UTD.htm?16/27/16821\">",
"     algorithm 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H32243317\">",
"     'Algorithm for estimating the likelihood of axial spondyloarthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The application of these various criteria requires a careful history, examination, and selected laboratory testing, as described below. Regardless, the first step in the decision process is assessing whether a patient has had back pain for more than three months and then determining whether or not it is an &ldquo;inflammatory back pain&rdquo; based upon the history.",
"   </p>",
"   <p>",
"    Patients who have clinical features suggestive of AS but who lack diagnostic radiographic changes may eventually develop typical AS. Thus, follow-up observations of patients suspected of SpA are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32243241\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key element in the evaluation of patients for AS or other SpA is to determine whether the patient&rsquo;s history is compatible with inflammatory back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The history should also include questioning regarding possible antecedent infectious illnesses; symptoms of inflammatory bowel disease, psoriasis, or uveitis; and a family history of spondyloarthritis, uveitis, psoriasis, or inflammatory bowel diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. The family history is, thus, of particular importance. A review of systems may identify symptoms suggesting extraarticular manifestations of AS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Extraarticular involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a thorough general medical history may identify symptoms of diseases that are considered in the differential diagnosis of AS. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32243565\">",
"    <span class=\"h4\">",
"     Inflammatory back pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following five characteristics performed best in a study to identify criteria which most clearly differentiated patients with chronic back pain (greater than three months in duration) due to axial spondyloarthritis from those with other causes of chronic back pain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of back discomfort before the age of 40 years",
"     </li>",
"     <li>",
"      Insidious onset",
"     </li>",
"     <li>",
"      Improvement with exercise",
"     </li>",
"     <li>",
"      No improvement with rest",
"     </li>",
"     <li>",
"      Pain at night (with improvement upon arising)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Presence of four of the five features listed above had a sensitivity and specificity of 77 and 92 percent, respectively, of the patients used to develop proposed criteria for inflammatory back pain and had a sensitivity and specificity of 80 and 74 percent, respectively, in the separate cohort of 648 patients used for validation of these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the prevalence of AS in the general population is low compared with that of other causes of back pain, the proportion of false positive diagnoses of AS is high if the presence of inflammatory back pain is used as the sole diagnostic criterion. About 20 percent of individuals with other causes of low back pain complain of symptoms similar to those of inflammatory back pain. Hence, the duration and character of the back pain determined from the patient&rsquo;s history cannot be relied upon as the only criteria for the diagnosis of AS. In addition, the calculated sensitivity of this set of criteria of 77 to 80 percent indicates that a number of patients with axial SpA will not have back pain which fulfills these criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AS have no single pathognomonic physical finding. The presence of limited spinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest mobility are suggestive of AS, and documenting the amount of motion in the back and chest provides a baseline from which the patient&rsquo;s progress with treatment can be measured. These measurements include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modified Schober test &mdash; Reduction of the range of motion of the lower back is a clinical feature of AS but is not specific for this disease. Assessment of spinal mobility has traditionally used the Schober test (",
"      <a class=\"graphic graphic_figure graphicRef58884 \" href=\"UTD.htm?6/39/6768\">",
"       figure 1",
"      </a>",
"      ). We favor the modified Schober (Macrae&rsquo;s modification), which is performed and interpreted as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With the patient standing erect, the position of the fifth lumbar spinous process is marked by a pen; additional marks are made 10 cm above and 5 cm below in the midline.",
"     </li>",
"     <li>",
"      The patient bends forward maximally, and the distance between the upper and lower marks is measured.",
"     </li>",
"     <li>",
"      People with normal spinal mobility have an increase in the measured distance of at least 5 cm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occiput to wall distance &mdash; Measurement of the occiput to wall distance (",
"      <a class=\"graphic graphic_figure graphicRef62964 \" href=\"UTD.htm?3/22/3439\">",
"       figure 2",
"      </a>",
"      ) provides another assessment of spinal mobility. Increasing occiput to wall distance is associated with loss of lumbar and cervical lordosis and with increasing thoracic spinal kyphosis.",
"     </li>",
"     <li>",
"      Chest expansion &mdash; Chest expansion is measured at the level of the fourth intercostal space or just below the breasts in females. The arms should be elevated above and hands should be folded behind the head. The patient is instructed to exert a maximal forced expiration followed by a maximal inspiration. The expansion is usually 5 cm or more. An expansion of less than 2.5 cm is abnormal.",
"     </li>",
"     <li>",
"      Sacroiliac joint tenderness &mdash; Patients who have pain in the region of the sacroiliac joints or the buttock may have tenderness elicited by direct pressure over the sacroiliac joint (",
"      <a class=\"graphic graphic_figure graphicRef69832 \" href=\"UTD.htm?7/28/7631\">",
"       figure 3",
"      </a>",
"      ). In addition, three physical maneuvers can be used to exert stress on the sacroiliac joint and to bring out sacroiliac pain. However, none of these physical examinations for sacroiliac involvement has been demonstrated to be specific for sacroiliitis. These include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With the patient lying supine, direct pressure is exerted by the examiner on the anterior superior iliac spine, and, at the same time, the iliac spine is forced laterally.",
"     </li>",
"     <li>",
"      With the patient lying on the side, pressure is exerted by the examiner to compress the pelvis (",
"      <a class=\"graphic graphic_figure graphicRef80283 \" href=\"UTD.htm?35/58/36782\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With the patient lying supine, he or she is instructed to flex one of the knees and then to abduct as well as externally rotate the corresponding hip. Pressure on the flexed knee causes pain at the corresponding sacroiliac joint (",
"      <a class=\"graphic graphic_figure graphicRef60605 \" href=\"UTD.htm?7/8/7311\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hip joint involvement &mdash; Examination of the hip for flexion deformities is particularly important because hip disease can be the initial presentation in children or adolescents and because it can be a cause of crippling disability in adults. Unilateral flexion deformity is frequently masked by compensatory motion in the spine. To eliminate this problem, the patient is asked to lie supine and to maximally flex one hip. If there is flexion deformity of the contralateral hip, the knee of the contralateral limb will be raised, and the degree of flexion deformity can be measured by the angle of the contralateral thigh (",
"      <a class=\"graphic graphic_figure graphicRef64736 graphicRef77527 \" href=\"UTD.htm?0/21/340\">",
"       figure 6A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Peripheral joint involvement &mdash; Peripheral joint pain and stiffness may be manifestations of synovitis or enthesitis. Symptomatic joints and accessible entheses are examined for tenderness, swelling, and range of motion.",
"     </li>",
"     <li>",
"      Enthesitis",
"      <strong>",
"       &mdash;",
"      </strong>",
"      The most obvious enthesitis is pain and swelling at the heel involving the Achilles tendon and insertion of the plantar fascia into the calcaneus.",
"     </li>",
"     <li>",
"      Dactylitis &mdash; Dactylitis is diffuse swelling of digits of toes or fingers, also termed &ldquo;sausage digits.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of the C-reactive protein (CRP) and determination of the presence or absence of HLA-B27, particularly among Caucasian and Chinese patients, are very useful and should be carried out in all patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phase reactants &mdash; The CRP or erythrocyte sedimentation rate (ESR) level should be measured in all patients suspected of AS. Elevated CRP constitutes one of the parameters in the ASAS classification criteria of axial SpA.",
"     </li>",
"     <li>",
"      HLA-B27 testing &mdash; All patients suspected of AS should be tested for HLA-B27 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3,6,9,10\">",
"       3,6,9,10",
"      </a>",
"      ]. Among Caucasians, HLA-B27 is present in 95 percent of those with AS but only in about 8 percent of the general population, and the prevalence of AS in the HLA-B27 positive population is only about 5 percent. Thus, positive testing for HLA-B27 alone is not diagnostic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9478364\">",
"    <span class=\"h3\">",
"     Response to NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A therapeutic trial of a nonsteroidal antiinflammatory drug (NSAID) is very useful in the diagnosis of axial spondyloarthropathy (SpA). Although patients with back pain of many causes may improve when treated with antiinflammatory doses of an NSAID, marked improvement in pain within 24 to 48 hours is one of the parameters in the classification criteria and is supportive of a diagnosis of SpA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients suspected of SpA should have an anterior-posterior plain radiograph of the pelvis to visualize the sacroiliac joints. If radiographs do not show evidence of sacroiliitis or if the diagnosis is uncertain yet SpA is strongly suspected, magnetic resonance imaging (MRI) should be the next step. Patients who have normal plain radiographs but inflammation by MRI are considered as having positive imaging findings of sacroiliitis. Computerized tomography (CT) and ultrasonography may also have utility in selected patients. (See",
"    <a class=\"local\" href=\"#H114663903\">",
"     'Plain radiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H114663896\">",
"     'MRI in patients with normal radiography'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H114663889\">",
"     'Other imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114663903\">",
"    <span class=\"h4\">",
"     Plain radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal appearing sacroiliac (SI) joint on plain radiographs is a hallmark of longstanding AS. A single anteroposterior view of the pelvis is generally adequate to document any diagnostically useful changes (widening, erosions, sclerosis, or ankylosis) of the SI joints and has the advantages of allowing assessment of the hips and of having a relatively low cost compared with other imaging techniques.",
"   </p>",
"   <p>",
"    For each plain radiograph, the right and left sacroiliac joint should be evaluated separately and should be assigned a grade as follows (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Plain pelvis radiographs of the sacroiliac joints'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 0: normal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63078 \" href=\"UTD.htm?42/63/44017\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade 1: suspicious changes (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56285 \" href=\"UTD.htm?2/63/3057\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade 2: minimal abnormality &mdash; small localized areas with erosions or sclerosis, without alteration in the joint width (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56285 \" href=\"UTD.htm?2/63/3057\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade 3: unequivocal abnormality &mdash; moderate or advanced sacroiliitis with one or more of the following: erosions, evidence of sclerosis, widening, narrowing, or partial ankylosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68009 graphicRef79174 \" href=\"UTD.htm?19/46/20199\">",
"       image 3A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade 4: severe abnormality &mdash; total ankylosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58791 graphicRef70511 \" href=\"UTD.htm?23/52/24392\">",
"       image 4A-B",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient is regarded as showing positive radiographic sacroiliitis if changes are greater than or equal to grade 2 bilaterally or greater than or equal to grade 3 unilaterally.",
"   </p>",
"   <p>",
"    Additional examples of the various grades are available in the slide library of the Assessment of SpondyloArthritis International Society (ASAS) at",
"    <a class=\"external\" href=\"file://www.asas-group.org/\">",
"     file://www.asas-group.org/",
"    </a>",
"    (accessed February 8, 2011).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114663896\">",
"    <span class=\"h4\">",
"     MRI in patients with normal radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a plain film radiograph does not fulfill the above criteria for sacroiliitis but the suspicion for AS remains high, the next imaging step is MRI (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74986 \" href=\"UTD.htm?26/16/26880\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58047 \" href=\"UTD.htm?38/7/39026\">",
"     image 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/11\">",
"     11",
"    </a>",
"    ]. The clinician caring for the patient should be involved in the evaluation of the MRI findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of 648 patients regarded as having axial SpA by the investigators, 34 percent of those who had normal or doubtful plain radiographs of the sacroiliac joints showed inflammation by MRI. A very small percentage of these patients had normal sacroiliac joints by both plain radiography and MRI but showed inflammatory changes in the spine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114663889\">",
"    <span class=\"h4\">",
"     Other imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with normal plain radiographs, for whom MRI is contraindicated (eg, because of a pacemaker, etc), can be assessed for evidence of sacroiliitis by computerized tomography (CT) scanning. Although CT of the sacroiliac joints is better than MRI and plain radiographs in visualizing erosions and bony sclerosis, it cannot detect acute inflammatory changes in the bone marrow. Routine use of CT is not recommended, because of the relatively high dose of gonadal radiation and because of a lack of consensus on how to interpret SI joint CT.",
"   </p>",
"   <p>",
"    Ultrasonography, although relatively less costly than MRI, is operator- and equipment-dependent. The potential of musculoskeletal ultrasonography to detect sacroiliitis and varying degrees of increased vascularity of the paraspinal tissues due to spondylitis needs to be more thoroughly evaluated before recommendations can be made regarding its use in clinical practice. Some data suggest that there may be a role for color Doppler ultrasound in early diagnosis of AS and in assessment of the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32243281\">",
"    <span class=\"h2\">",
"     Criteria used for classification and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most of the studies of AS since their publication, selection of AS patients has been based upon the 1984 Modified New York Criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2009 and 2010, the Assessment of SpondyloArthritis International Society (ASAS) published two separate sets of classification criteria for SpA: the ASAS classification criteria for axial SpA and the ASAS classification criteria for peripheral SpA, respectively. AS belongs to the category of axial SpA as defined by the ASAS criteria. A useful reference is The Assessment of SpondyloArthritis International Society (ASAS) Handbook: A guide to assess spondyloarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9478399\">",
"    <span class=\"h3\">",
"     ASAS classification criteria for axial SpA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASAS classification criteria for axial SpA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/2\">",
"     2",
"    </a>",
"    ] are especially useful for those patients early in the disease with normal plain radiographs of the sacroiliac joints [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/2\">",
"     2",
"    </a>",
"    ]. Plain radiographic changes of sacroiliitis take two or more years of disease duration to appear. Patients who satisfy the classification criteria for axial SpA but who do not have plain radiographic sacroiliitis are labelled as non-radiographic axial SpA (nr-axSpA). About 12 percent of these patients develop radiographic changes in the sacroiliac joints over two years of follow-up and can then be labelled as AS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To be classified as having axial SpA, a patient will need to first satisfy the first entry criteria. This is that the patient must have had back pain for at least three months plus an age of onset of less than 45 years.",
"   </p>",
"   <p>",
"    A patient who satisfies the first level of entry criteria should then be considered at a second level of entry criteria. There are two parameters in the second level of entry criteria shown below as features A and B:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Feature A &mdash; Sacroiliitis on imaging studies. The definition of sacroiliitis will be described in a separate section below. If the imaging is positive, a patient can be classified as having axial SpA if the patient also has one or more of the features in the list of SpA feature shown below.",
"     </li>",
"     <li>",
"      Feature B &mdash; HLA-B27 positivity. A HLA-B27 positive patient can be classified as having axial SpA if the patient has two or more of the features in the list of SpA features shown below, whether or not sacroiliitis is present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SpA features used in the ASAS classification criteria of axial SpA include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory back pain (see",
"      <a class=\"local\" href=\"#H32243565\">",
"       'Inflammatory back pain'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Arthritis &mdash; diagnosed clinically by a physician",
"     </li>",
"     <li>",
"      Enthesitis &mdash; diagnosed clinically by a physician",
"     </li>",
"     <li>",
"      Uveitis &mdash; past or present anterior uveitis, diagnosed by an ophthalmologist",
"     </li>",
"     <li>",
"      Dactylitis &mdash; diagnosed by a physician",
"     </li>",
"     <li>",
"      Psoriasis &mdash; diagnosed by a physician",
"     </li>",
"     <li>",
"      Inflammatory bowel disease (IBD) &mdash; Crohn&rsquo;s disease or ulcerative colitis diagnosed by a physician",
"     </li>",
"     <li>",
"      Good response to NSAIDs (nonsteroidal antiinflammatory drugs) &mdash; back pain becomes either absent or much better 24 to 48 hours after starting a full dose of NSAID",
"     </li>",
"     <li>",
"      Family history of SpA &mdash; presence in first-degree or second-degree relatives of any of the following: AS, acute uveitis, reactive arthritis",
"     </li>",
"     <li>",
"      HLA-B27-positivity",
"     </li>",
"     <li>",
"      Elevated CRP &mdash; above the upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of this set of criteria are 83 and 84 percent, respectively, when expert opinion is used as the &ldquo;gold standard.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32243117\">",
"    <span class=\"h3\">",
"     Modified New York criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;For almost all research carried out since the mid-1980s, patients have been regarded as having ankylosing spondylitis only if they fulfill the 1984 Modified New York Criteria for ankylosing spondylitis. This set of criteria consists of a subset of clinical parameters and a subset of radiological parameters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical parameters",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low back pain and stiffness for more than three months that improves with exercise but that is not relieved by rest",
"     </li>",
"     <li>",
"      Limitation of motion of the lumbar spine in both the sagittal and frontal planes",
"     </li>",
"     <li>",
"      Limitation of chest expansion relative to normal values correlated for age and sex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiological parameters using plain radiographs alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sacroiliitis grade &ge;2 bilaterally",
"     </li>",
"     <li>",
"      Sacroiliitis grade 3 to 4 unilaterally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient is regarded as having definite AS if he or she fulfills at least one radiological parameter plus at least one clinical parameter.",
"   </p>",
"   <p>",
"    In clinical practice, this set of criteria is useful for patients with classical AS. For other patients, the ASAS classification criteria for axial spondyloarthritis are more useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\", section on 'Musculoskeletal imaging features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32243317\">",
"    <span class=\"h3\">",
"     Algorithm for estimating the likelihood of axial spondyloarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients cannot be diagnosed with certainty as having SpA, but the likelihood of disease can be estimated by use of an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80964 graphicRef59693 \" href=\"UTD.htm?16/27/16821\">",
"     algorithm 1A-B",
"    </a>",
"    ) developed from the published literature that is based upon the history and findings in the patient under evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other types of systemic arthritis may need to be distinguished from AS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid arthritis can usually be easily differentiated from AS since it predominantly affects small peripheral joints in a symmetrical pattern, is often rheumatoid factor or anticyclic citrullinated peptide antibody (anti-CCP) positive, and is not associated with HLA-B27. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reactive arthritis and psoriatic arthritis can involve sacroiliac joints and can be associated with HLA-B27. A history of a preceding intestinal or genitourinary tract infection suggests reactive arthritis, while the presence of typical psoriatic skin or nail changes is usually noted in psoriatic arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"       \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The spondyloarthropathy associated with inflammatory bowel disease may be part of the spectrum of AS, with some patients not developing clinical signs of bowel disease for several years after the onset of the arthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13640/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=see_link\">",
"       \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In diffuse idiopathic skeletal hyperostosis (DISH, also known as Forestier&rsquo;s disease), the following findings are observed: the sacroiliac joints are usually spared; the apophyseal joints are not ankylosed; exuberant osteophyte formation and flowing calcification occur; at least four contiguous vertebral bodies are ossified; and disc height is maintained. There may be extraspinal involvement with hyperostosis noted in the region of the olecranon, patella, calcaneus, shoulder, and acetabulum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=see_link\">",
"       \"Diffuse idiopathic skeletal hyperostosis (DISH)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"       \"Patient information: Ankylosing spondylitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of ankylosing spondylitis (AS) can be aided by evaluating the parameters in the Modified New York Criteria for Ankylosing Spondylitis, the ASAS classification criteria for Axial Spondyloarthritis, and also an algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef80964 graphicRef59693 \" href=\"UTD.htm?16/27/16821\">",
"       algorithm 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32243281\">",
"       'Criteria used for classification and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thorough medical history, physical examination, and selected laboratory and imaging tests are used in diagnosis of AS and in the exclusion of other disorders considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A patient with chronic inflammatory back pain and evidence of x-ray changes of sacroiliitis has a very high likelihood of having AS. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may be diagnosed with axial spondyloarthritis prior to developing plain radiographic features of sacroiliitis, if they have sacroiliitis demonstrated by MRI or if they are HLA-B27 positive and have one to two additional features of spondyloarthritis, respectively, such as an elevated CRP and a good response to NSAIDs. (See",
"      <a class=\"local\" href=\"#H32243281\">",
"       'Criteria used for classification and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A therapeutic trial of antiinflammatory doses of an NSAID (eg, two weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      500 mg three times daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      150 mg daily) may aid in diagnosis. A substantial reduction in pain and stiffness with this regimen supports an inflammatory etiology of back pain and stiffness. (See",
"      <a class=\"local\" href=\"#H9478364\">",
"       'Response to NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have clinical features suggestive of AS but who lack diagnostic radiographic changes may eventually develop typical AS. Follow-up observations of patients suspected of SpA are required. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/1\">",
"      van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/2\">",
"      Rudwaleit M, van der Heijde D, Landew&eacute; R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/3\">",
"      Rudwaleit M, van der Heijde D, Khan MA, et al. How to diagnose axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/4\">",
"      Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/5\">",
"      Sieper J, van der Heijde D, Landew&eacute; R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/6\">",
"      Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/7\">",
"      Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007; 34:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/8\">",
"      Chandran V, O'Shea FD, Schentag CT, et al. Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol 2007; 34:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/9\">",
"      Rudwaleit M, Metter A, Listing J, et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/10\">",
"      Liu X, Li YR, Hu LH, et al. High frequencies of HLA-B27 in Chinese patients with suspected of ankylosing spondylitis. Rheumatol Int 2010; 30:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/11\">",
"      Klauser A, Bollow M, Calin A, et al. Workshop report: clinical diagnosis and imaging of sacroiliitis, Innsbruck, Austria, October 9, 2003. J Rheumatol 2004; 31:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/12\">",
"      Blachier M, Coutanceau B, Dougados M, et al. Does the site of magnetic resonance imaging abnormalities match the site of recent-onset inflammatory back pain? The DESIR cohort. Ann Rheum Dis 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/13\">",
"      Unl&uuml; E, Pamuk ON, Cakir N. Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy? J Rheumatol 2007; 34:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/14\">",
"      O'Shea F, Salonen D, Inman R. The challenge of early diagnosis in ankylosing spondylitis. J Rheumatol 2007; 34:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/15\">",
"      de Miguel E, Cobo T, Mu&ntilde;oz-Fern&aacute;ndez S, et al. Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 2009; 68:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/16\">",
"      Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/17\">",
"      Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol 2012; 24:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/18\">",
"      De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/19\">",
"      Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13640/abstract/20\">",
"      Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37:23.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7786 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13640=[""].join("\n");
var outline_f13_20_13640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32243241\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H32243565\">",
"      Inflammatory back pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9478364\">",
"      - Response to NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H114663903\">",
"      Plain radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H114663896\">",
"      MRI in patients with normal radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H114663889\">",
"      Other imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32243281\">",
"      Criteria used for classification and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9478399\">",
"      - ASAS classification criteria for axial SpA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32243117\">",
"      - Modified New York criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32243317\">",
"      - Algorithm for estimating the likelihood of axial spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7786|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/2/29743\" title=\"algorithm 1A\">",
"      Decision tree axial SpA primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/37/20049\" title=\"algorithm 1B\">",
"      Decision tree axial SpA rheum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7786|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/63/44017\" title=\"diagnostic image 1\">",
"      Sacroiliitis grade 0",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/63/3057\" title=\"diagnostic image 2\">",
"      Sacroiliitis grade 1 and 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/34/35362\" title=\"diagnostic image 3A\">",
"      Sacroiliitis grade 3 example 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/62/24545\" title=\"diagnostic image 3B\">",
"      Sacroiliitis grade 3 example 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?32/11/32945\" title=\"diagnostic image 4A\">",
"      Sacroiliitis grade 4 example 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/55/4981\" title=\"diagnostic image 4B\">",
"      Sacroiliitis grade 4 example 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/16/26880\" title=\"diagnostic image 5\">",
"      MRI sacroiliitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/7/39026\" title=\"diagnostic image 6\">",
"      MRI in normal versus SpA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7786|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/39/6768\" title=\"figure 1\">",
"      Low back flexion test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/22/3439\" title=\"figure 2\">",
"      Cervical flexion deformity AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/28/7631\" title=\"figure 3\">",
"      Sacroiliac tenderness I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/58/36782\" title=\"figure 4\">",
"      Sacroiliac tenderness II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/8/7311\" title=\"figure 5\">",
"      Sacroiliac tenderness III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/54/7023\" title=\"figure 6A\">",
"      Flexion hip deformity in AS I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/30/29152\" title=\"figure 6B\">",
"      Flexion hip deformity in AS II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/59/43960?source=related_link\">",
"      Diffuse idiopathic skeletal hyperostosis (DISH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=related_link\">",
"      Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=related_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13641="Skin in disseminated histo";
var content_f13_20_13641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74799%7EID%2F67381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74799%7EID%2F67381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated histoplasmosis in a patient with AIDS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized maculopapular eruption and vesiculopustules resemble varicella zoster virus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD. Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Biopsy specimen from a facial lesion (gomori methenamine silver stain; original magnification, x600)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13641=[""].join("\n");
var outline_f13_20_13641=null;
var title_f13_20_13642="Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults";
var content_f13_20_13642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13642/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13642/contributors\">",
"     Christopher P Denton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13642/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/20/13642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/20/13642/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/20/13642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma encompasses a spectrum of related disorders, most of which share a characteristic clinical feature of skin thickening due to an excess of collagen fibers. The classification of scleroderma is presented separately, but a brief summary is included for the purpose of this overview of treatment. The simplest division of the scleroderma-related disorders is into localized and systemic forms of the disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Localized scleroderma can be divided into (",
"    <a class=\"graphic graphic_table graphicRef60398 \" href=\"UTD.htm?1/22/1388\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morphea",
"     </li>",
"     <li>",
"      Linear scleroderma",
"     </li>",
"     <li>",
"      En coup de sabre",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the extent of skin involvement and the accompanying pattern of internal organ involvement form the basis for the current (and most popular) classification of systemic sclerosis (SSc) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/1\">",
"     1",
"    </a>",
"    ]. The principal subsets of SSc are (",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"UTD.htm?3/41/3741\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse cutaneous systemic sclerosis (dcSSc)",
"     </li>",
"     <li>",
"      Limited cutaneous systemic sclerosis (lcSSc)",
"     </li>",
"     <li>",
"      Systemic sclerosis sine scleroderma (patients with only internal organ involvement)",
"     </li>",
"     <li>",
"      Environmentally-induced scleroderma",
"     </li>",
"     <li>",
"      Overlap syndromes (features of systemic sclerosis which coexist with elements of other rheumatic disorders)",
"     </li>",
"     <li>",
"      Pre-scleroderma (patients with the Raynaud phenomenon plus positive autoantibodies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal nailfold capillaroscopy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain autoantibodies found in systemic sclerosis are associated with subsets of the disease. The presence of some of these autoantibodies may also predict the risk of future organ involvement (",
"    <a class=\"graphic graphic_table graphicRef59732 \" href=\"UTD.htm?10/18/10541\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of the scleroderma disorders are poorly understood (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=see_link\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    ) and, as a consequence, treatment of these conditions is difficult, incomplete, and not curative.",
"   </p>",
"   <p>",
"    Despite these difficulties, a differentiation between localized and systemic disease and an understanding of the SSc subsets, disease staging, organ involvement, and pathogenesis permits the most effective use of current therapies and the adoption of a strategy of disease containment.",
"   </p>",
"   <p>",
"    An overview of the management of adults with SSc will be discussed here. Discussions of localized and systemic scleroderma disorders in children are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39433?source=see_link\">",
"     \"Juvenile systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fear is engendered in many SSc patients since the disorder can threaten not only their physical and functional abilities but also their professional, social, and emotional lives [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the overall management of SSc requires a high level of education and encouragement of patients in combination with a team approach to care. The team should include the patient, family, physicians, physiotherapists, nurse educators, occupational therapists, social workers, counselors and community services. Input from patient support groups can also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the initial pretreatment assessment is to determine the distribution of organ involvement and, if possible, to decide whether organ dysfunction is related to potentially reversible inflammation or vasoconstriction (active disease) or whether the damage is irreversible with current therapies (eg, fibrosis or ischemic necrosis). An approach to pretreatment evaluation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37045?source=see_link\">",
"     \"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The medical history, physical examination, laboratory tests, and imaging studies that lead to an initial diagnosis of SSc, provide much of the information necessary to determine the distribution of organ involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functional tests, additional imaging studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organ biopsy may be necessary to determine the distribution, severity, and nature of scleroderma-related processes prior to developing a treatment plan. For each potentially affected organ, particular tests are often recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMMUNOMODULATORY AND ANTIFIBROTIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic immunologic modulation and potentially antifibrotic approaches are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=see_link\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .) Patients with alveolitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary fibrosis due to SSc may benefit from use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Interstitial fibrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ORGAN BASED TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections provide an overview of the approach to assessment and treatment of scleroderma and other organ involvement in SSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment of localized sclerotic skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preliminary studies, the lesions of localized scleroderma, including morphea, appear to soften with ultraviolet-A (UVA) light therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Other options include highly potent topical glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/54/5988?source=see_link\">",
"     calcipotriol",
"    </a>",
"    (a vitamin D analog), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The combination of high-dose systemic glucocorticoids and low dose methotrexate has also been used, but any patients that show additional features of systemic sclerosis (SSc) must be very carefully monitored, because high-dose glucocorticoids may increase the risk of scleroderma renal crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17640?source=see_link\">",
"     \"Treatment of morphea (localized scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapies that are being investigated for treatment of skin thickening include the use of a humanized anti-transforming growth factor (TGF) beta-1 monoclonal antibody, the plant alkaloid halofuginone that interferes with TGF-beta induced type I collagen production, topical TGF-beta-1 binding peptides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/10,11\">",
"     10,11",
"    </a>",
"    ],",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment of widespread skin sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible efficacy of systemic approaches to the treatment of the diffuse and limited cutaneous subsets is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=see_link\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intense pruritus can occur in the earliest stages of dcSSc, and excessive scratching and excoriation may be a major problem. There is little immediate effective therapy; fortunately, pruritus usually decreases as the disease plateau.",
"   </p>",
"   <p>",
"    Antihistamines may help, but can cause drowsiness. Maintaining adequate lubrication of the skin is essential and patients should use lubricating creams, especially those that are lanolin-based. Patients should minimize contact with water. Low-dose oral glucocorticoids are sometimes effective for severe pruritus. Topical steroids are rarely helpful. Counter-irritants may also be used. There are anecdotal reports that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    may be effective, but formal trials have not been performed with these agents, and they are not licensed for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasia can be a cosmetic problem, particularly on the face. These lesions can be covered with green foundation make-up. Laser or other light therapy may be useful for particularly large lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Calcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcinosis causes great distress. Pharmacologic attempts to dissolve or prevent new lesions in patients with calcinosis using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    have failed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     Diltiazem",
"    </a>",
"    has been suggested as possible therapy for calcinosis of the skin (calcinosis cutis). In one study, four of four patients treated with diltiazem exhibited marked clinical improvement following use of the calcium channel blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium channel blockers are often administered to patients with SSc related calcinosis and may help symptoms of Raynaud phenomenon (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Raynaud phenomenon'",
"    </a>",
"    below). Their effects on calcinosis remain unproven.",
"   </p>",
"   <p>",
"    Suitably located lesions can be removed surgically, sometimes by using a dental drill; this technique causes less tissue damage than conventional methods. Calcinosis may also be associated with ulcerating lesions which can become infected and require antibiotics, vigorous local therapy, and possible removal. In occasional patients, an inflammatory reaction rather similar to pseudogout occurs; this manifestation should be treated with nonsteroidal antiinflammatory drugs. There is one report of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    therapy benefiting digital calcinosis in a small open-label study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular involvement is a prominent feature of SSc. A common manifestation is the Raynaud phenomenon. Vasoconstriction and obliterative vasculopathy may contribute to the Raynaud phenomenon, scleroderma renal crisis, pulmonary hypertension and to other visceral disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selected issues specifically related to treatment of Raynaud phenomenon in patients with SSc are presented below. Treatment of the vascular component of SSc renal and lung disease are discussed later (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Renal'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Pulmonary hypertension'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold-induced skin color changes, typically blanching, followed by cyanosis then reactive hyperemia are seen in the majority of patients with SSc. Prolonged ischemia may lead to necrotic lesions or digital amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of the Raynaud phenomenon (RP) should be performed in a graduated fashion. Avoidance of cold, stress, nicotine, caffeine, and sympathomimetic decongestant medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19190?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    ) are valuable nonpharmacologic elements to prevent or avoid exacerbating the Raynaud phenomenon (RP).",
"   </p>",
"   <p>",
"    A wide variety of treatment options are available for RP at present (",
"    <a class=\"graphic graphic_table graphicRef55300 \" href=\"UTD.htm?22/57/23453\">",
"     table 4",
"    </a>",
"    ). However, these therapies only provide symptomatic relief; they do not cure the disease. Treatment of RP in patients with SSc is generally the same as for others with the disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link\">",
"     \"Initial treatment of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some agents used for treating other features of SSc may also have a role in treating Raynaud phenomenon. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       Bosentan",
"      </a>",
"      &mdash; The nonselective endothelin antagonist, bosentan, which has been approved for treatment of pulmonary hypertension in patients with SSc, may have a beneficial effect upon digital ischemia and may reduce the incidence of digital ulceration. This was illustrated in a multicenter study that randomly assigned 122 patients with SSc to receive bosentan (62.5 mg BID with dose escalation to 125 mg BID as tolerated), or placebo for 16 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/14\">",
"       14",
"      </a>",
"      ]. The mean number of new digital ulcers that developed was significantly less in those receiving bosentan than placebo (1.4 versus 2.7 per patient); for the subset of patients with at least one digital ulcer at the initial visit, the incidence of new ulcers was decreased by 50 percent with bosentan.",
"      <br/>",
"      <br/>",
"      Although this approach may prevent new ulcers it is uncertain whether the healing of established digital ulcers is facilitated. As has been noted in patients treated for pulmonary hypertension, elevation of serum aminotransferases was more frequent in the bosentan treated group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link&amp;anchor=H4#H4\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\", section on 'Endothelin-1 receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parenterally administered prostacyclin analogs &mdash; The synthetic analogue of prostacyclin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      (carbaprostacyclin, given parenterally at 0.5 to 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per min), is a potent vasodilator that also inhibits platelet aggregation and adhesion, increases red blood cell deformability, alters neutrophil function (including free-radical production), and may help repair damaged endothelium. It also decreases the production and release of the profibrotic cytokine, connective tissue growth factor from fibroblasts, thereby reducing its concentration in sclerodermatous skin [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The possible efficacy of iloprost was evaluated in a double-blind, controlled trial in which 131 patients with Raynaud phenomenon secondary to SSc were randomly assigned to either placebo or iloprost (given as five daily sequential six hour infusions at a dose of 0.5 to 2.0",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per min) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/16\">",
"       16",
"      </a>",
"      ]. Iloprost was effective for the short-term palliation of severe Raynaud phenomenon in SSc, although side effects were more common during the iloprost infusion. It may help to avoid amputation of the distal tip of a digit. However, intravenous iloprost is not available in the United States. The following benefits were noted in the patients treated with iloprost after at least six weeks follow-up:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A greater reduction in the number of weekly attacks (39 versus 22 percent with placebo)",
"     </li>",
"     <li>",
"      A greater mean reduction in the global Raynaud severity score (35 versus 20 percent)",
"     </li>",
"     <li>",
"      15 percent more patients showed healing of at least 50 percent of digital cutaneous lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orally administered prostacyclin analogs &mdash; Efforts have been made to develop an oral prostacyclin analog that is safe and effective. One such analog, beraprost, was evaluated in a prospective placebo-controlled randomized study of 107 patients with SSc and digital necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/17\">",
"       17",
"      </a>",
"      ]. Active therapy was associated with a nonsignificant trend for benefit.",
"     </li>",
"     <li>",
"      Phosphodiesterase type-5 inhibitors &mdash; The use of phosphodiesterase type-5 inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      &nbsp;and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      , which are also sometimes employed for the management of pulmonary hypertension, is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"       \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with SSc and Raynaud phenomenon that does not respond to medical management, surgery may be necessary. Different forms of sympathectomy have been tried in an attempt to treat severe Raynaud phenomenon. Cervical sympathectomy is rarely used since it often provides only short-term benefits. By contrast, lumbar sympathectomy provides long-term beneficial effects for severe vasoconstriction of the feet. This discrepancy between the effectiveness of the procedure in the upper and lower limbs is not understood.",
"   </p>",
"   <p>",
"    Radical microarteriolysis (digital sympathectomy) has been found to relieve severe pain, heal digital ulcers and often reduce the severity of the attacks of Raynaud phenomenon. However, complication rates are relatively high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9958?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgery in patients with systemic sclerosis (scleroderma) of the hand\", section on 'Digital ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In very severe cases with digital gangrene, the surgeon sometimes debrides a finger, removes an infected nail, and, as a last resort, performs an amputation. These procedures may be preceded by an infusion of a prostacyclin drug, which is often effective in preventing or delaying surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link&amp;anchor=H785254#H785254\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\", section on 'Digital ulceration with critical ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concepts of maintenance of vascular tone and interventions with the potential to prevent damage to the vessel wall in SSc may result in future therapeutic developments (",
"    <a class=\"graphic graphic_table graphicRef57635 \" href=\"UTD.htm?42/26/43436\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure, serum creatinine, GFR, urinalysis, and urine protein (24 hour urine or urine",
"    <span class=\"nowrap\">",
"     protein/creatinine",
"    </span>",
"    ratio) are helpful to measure initially and to monitor as indicators of renal disease in SSc. The finding of elevated or rising blood pressure, decreased or declining renal function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heavy proteinuria are concerning for scleroderma renal crisis (",
"    <a class=\"graphic graphic_algorithm graphicRef74898 \" href=\"UTD.htm?31/39/32383\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring is most important during the first five years of SSc, since most cases of renal disease occur by this time. The following regimen of monitoring is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure measurement is recommended on a monthly basis. For patients who show any signs of a rising, but still normal, blood pressure without evidence of renal disease, we switch to home blood pressure measurement several times per week.",
"     </li>",
"     <li>",
"      Estimation of the GFR and dipstick testing for protein or calculation of the protein-to-creatinine ratio on a random urine specimen every three to six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"       \"Assessment of kidney function\", section on 'Estimation equations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A documented fall in GFR of 20 percent or more or new and persistent proteinuria above 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are important warning signs of impending renal crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Treatment of hypertension and renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of blood pressure is the mainstay of treatment of scleroderma renal crisis. Angiotensin converting enzyme (ACE) inhibitors are the first-line antihypertensive agents in this setting. The most reported experience has been with the short acting agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    . If use of an ACE inhibitor alone is inadequate to control hypertension, then a calcium channel blocker can be added, and other antihypertensive agents may be needed in combination. Agents with beta blocking activity should be avoided as they may worsen digital ischemia. Angiotensin receptor blockers are an option in patients who cannot tolerate ACE inhibitors, although they have not been shown to be as effective as ACE inhibitors in established renal crisis. They may be added to ACE inhibitors in cases of refractory hypertension in SRC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H18#H18\">",
"     \"Scleroderma renal crisis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal replacement therapy with hemodialysis or peritoneal dialysis may be needed for acute renal failure. Renal function may improve with appropriate treatment of scleroderma renal crisis, but may be delayed and maximal improvement may take many months, thus ACE inhibitor therapy should be continued, and decisions regarding renal transplantation should be postponed, for at least two years after dialysis is begun. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H18#H18\">",
"     \"Scleroderma renal crisis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal involvement is very prevalent in SSc and may involve any or all portions from the mouth to the anus. Assessment of gastrointestinal manifestations is based primarily on symptomatology. Gastroesophageal reflux, delayed gastric emptying, intestinal hypomotility, bacterial overgrowth, malabsorption, diarrhea, and fecal incontinence are some of the problems for which treatment is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility that dysphagia is due to a scleroderma-associated myopathy, particularly a polymyositis-like inflammatory disorder, should be considered and testing, such as serum muscle enzymes, used to assess for the presence of this potentially reversible problem (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Inflammatory myopathy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Treatment of GI manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although 90 percent or more of SSc patients have abnormal esophageal motility, approximately 40 percent of patients with scleroderma-related esophageal reflux are asymptomatic. The empiric use of acid reducing agents, particularly proton pump inhibitors, is generally recommended in order to prevent the development of esophageal strictures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11415?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)\", section on 'Esophageal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prokinetic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    may be valuable for patients with esophageal hypomotility. The availability of cisapride, another prokinetic agent, has been restricted in the United States and Europe because of a potentially fatal prolongation of the QT interval and predisposition to ventricular tachycardia. The combination of erythromycin and cisapride must be avoided because concomitant use potentiates this adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manifestations of small bowel disease among patients with SSc consist of malabsorption and steatorrhea, dysmotility, and recurrent pseudo-obstruction. Malabsorption is typically treated with rotating antibiotics. Malabsorption and malnutrition related to small bowel failure that is unresponsive to such treatments may require parenteral nutrition. Treatment of dysmotility and intestinal pseudo-obstruction with prokinetic agents has generally not been effective. Parenteral nutrition and surgery may be necessary in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11415?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)\", section on 'Small intestinal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major types of lung disease in SSc:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenchymal disease (previously called fibrosing alveolitis) that can lead to interstitial fibrosis (interstitial lung disease or ILD)",
"     </li>",
"     <li>",
"      Pulmonary vascular disease, leading to pulmonary hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients may have a combination of interstitial disease and pulmonary vascular involvement.",
"   </p>",
"   <p>",
"    Respiratory muscle weakness may contribute to dyspnea. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Inflammatory myopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Interstitial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is presumed, but not proven, that alveolitis precedes the development of interstitial fibrosis.",
"   </p>",
"   <p>",
"    Symptoms of lung involvement include: fatigue, breathlessness on exertion (and eventually at rest), and a dry cough. Crackles are frequently present on chest examination, and may be widespread or predominantly basilar. Plain radiographs typically show no specific abnormalities in early alveolitis, but pulmonary function tests (including lung volumes and diffusing capacity for carbon monoxide), high-resolution CT scanning are more sensitive tests and are recommended to assess for pulmonary involvement prior to treatment and at yearly intervals thereafter. Bronchoalveolar lavage (BAL)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lung biopsy may be necessary in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Interstitial lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of fibrosis &mdash; Treatment is often recommended, if the presence of alveolitis is strongly suggested by findings on CT scan or examination of BAL fluid or is confirmed by lung biopsy, especially if there is evidence of progressive disease. Therapy for alveolitis typically consists of some combination of a glucocorticoid and immunosuppressive agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=see_link\">",
"       \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because there is no current treatment that can reverse the fibrotic process, if there is no evidence of active alveolitis, consideration should be given to enrollment in a trial of an investigational therapy for ILD and, for those with severe disease, to lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension in SSc may be due to one or more of the following: ILD, increased pulmonary arterial vasoreactivity, or obliterative vasculopathy. Clinical features suggesting pulmonary hypertension in the absence of ILD are: dyspnea, a prominent pulmonic component of the second heart sound, enlarged pulmonary arteries with oligemic lung fields on chest x-ray; normal imaging studies; and relatively normal lung volumes with a disproportionately reduced gas transfer as estimated from the DLCO corrected for alveolar volume.",
"   </p>",
"   <p>",
"    Dyspnea is present in approximately two-thirds of patients with documented pulmonary hypertension. Non-invasive assessment of pulmonary artery pressures by echocardiography is feasible in patients who have at least some tricuspid regurgitation. Echocardiography, when compared to right-heart catheterization for the detection of pulmonary hypertension, has a sensitivity of approximately 90 percent and specificity of 75 percent. We recommend echocardiographic examination of all patients with SSc at baseline and yearly intervals thereafter, with additional monitoring of lung function tests and dyspnea. Clinical suspicion should prompt further assessment by right heart catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\", section on 'Pulmonary arterial hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of pulmonary hypertension &mdash; The therapeutic options for treatment of pulmonary hypertension associated with SSc include the endothelin receptor antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      , the phosphodiesterase-5 inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      and various prostacyclin analogs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      ). Prostaglandin analogues may be administered by inhalation, subcutaneous infusion or intravenously. Vasodilator responsiveness among patients with SSc-associated pulmonary hypertension is rare, thus calcium channel antagonists are not usually of value. Balloon atrial septostomy may improve function and relieve symptoms in selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=see_link\">",
"       \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"       \"Treatment of pulmonary hypertension in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Lung transplantation (one or two lungs) or a combined heart-lung transplant may be an option for some patients who do not respond to medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].Patients with minimal extrapulmonary disease, particularly those in the limited cutaneous subset are better candidates than those with diffuse disease and concomitant issues such as malnutrition or renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"       \"Lung transplantation: General guidelines for recipient selection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthralgias, myalgias, and puffiness of the skin may be initial features of SSc. Features of early dcSSC are arthritic symptoms (sometimes severe) and tendon friction rubs. Sclerotic skin may also contribute to limiting joint motion the development of joint contractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Arthralgia and/or arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthritic symptoms often require analgesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NSAIDs; low-dose glucocorticoids to control the pain and inflammation are infrequently required; if used, they enhance the risk of developing renal complications.",
"   </p>",
"   <p>",
"    Physical therapy is important in limiting contractures (which can occur quite rapidly). Therapy should include both active and passive exercises. Adequate analgesia may be required to permit a regular daily regimen. Encouragement from the therapist and physician is also critical if a regular program is to be performed. The patient should appreciate that skin involvement ultimately plateaus, and that the purpose of physical therapy is to limit the loss of function before this occurs.",
"   </p>",
"   <p>",
"    Surgery has an uncertain role in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/22\">",
"     22",
"    </a>",
"    ]. Realignment of contracted fingers by straightening, shortening, and fusing of interphalangeal joints may improve the appearance and decrease the development of digital ulcers. However, such procedures may not greatly improve function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9958?source=see_link\">",
"     \"Surgery in patients with systemic sclerosis (scleroderma) of the hand\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Inflammatory myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild myopathy with little biochemical or histological change is a common feature of SSc. A smaller group of patients have an inflammatory myopathy. In the latter group, proximal weakness and other features such as elevation of serum muscle enzymes (creatine kinase, aldolase, and aminotransferases), abnormal electromyography, magnetic resonance imaging, and muscle biopsy findings are indistinguishable from idiopathic inflammatory myopathy (polymyositis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility that myopathy is contributing to symptoms such as dyspnea and dysphagia should be considered and appropriate testing (muscle enzymes, respiratory muscle strength ie, maximal inspiratory and expiratory pressures) utilized.",
"   </p>",
"   <p>",
"    Treatment of patients with SSc and an inflammatory myopathy is similar to that for patients with idiopathic polymyositis. Glucocorticoids alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or other immunosuppressive agents is generally employed. The desire to give high-dose steroids in this setting must be tempered by the increased risk of precipitating scleroderma renal crisis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct cardiac manifestations of scleroderma (ie, those not induced by systemic or pulmonary hypertension) include pericarditis, pericardial effusion, myocardial fibrosis, myocarditis, coronary artery disease, and arrhythmias. Symptoms due to these cardiac problems are nonspecific and include: chest pain, dyspnea, palpitations, and syncope. Physical findings that may be indicative of cardiac or pericardial involvement include: irregular heart rhythm or abnormal rate, jugular venous distention, Kussmaul sign, pulsus paradoxus, and peripheral edema. Tests that are recommended in the presence of symptoms suggesting cardiac involvement include: electrocardiography, plain chest radiograph, serum creatine kinase and troponin-I, and echocardiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Cardiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis typically causes chest pain, but effusive disease causing cardiac tamponade physiology may be painless and present with dyspnea and edema. A pericardial friction rub is typically present in those with chest pain due to pericarditis, while jugular venous distention, Kussmaul sign, pulsus paradoxus, and peripheral edema are indicative of a hemodynamically significant pericardial effusion or constriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment &mdash; Chest pain due to pericarditis in the absence of evidence of tamponade is treated with an NSAID unless there are contraindications (eg, impaired renal function, concomitant anticoagulation). Pericarditis refractory to NSAIDs may require use of glucocorticoids, but with the caveat that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or similar agents may increase the risk of developing scleroderma renal crisis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Renal'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Cardiac tamponade typically necessitates drainage of the effusion. The choice between open drainage and pericardiocentesis is a matter of local preference and experience, and also must be individualized for each patient. Catheter accomplished pericardiocentesis is the treatment of choice in most patients. Direct surgical visualization may be preferable if fluid has reaccumulated, the effusion is loculated, there is a special need for biopsy material, or the patient has a coagulopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"       \"Cardiac tamponade\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The efficacy of pericardiectomy for recurrent pericardial effusions is uncertain and has not been studied specifically in patients with SSc. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=see_link&amp;anchor=H14#H14\">",
"       \"Recurrent pericarditis\", section on 'Role of pericardiectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Myocardial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial fibrosis is present in up to 90 percent of SSc autopsies. Symptoms due to myocardial fibrosis may arise from heart failure, of either a restrictive or dilated type (eg, dyspnea, edema), or may be due to cardiac rhythm disturbances resulting from interference with normal cardiac electrical conduction (eg, palpitations, syncope). Myocardial scarring and fibrosis may also contribute to the development of atrial fibrillation.",
"   </p>",
"   <p>",
"    Heart failure associated with left ventricular dysfunction may be improved by glucocorticoids. However, restrictive cardiomyopathy is not likely to respond to steroids. If heart failure is noted in conjunction with an elevation of a marker of cardiac injury, such as CK-MB or troponin-I that is not due to epicardial coronary artery disease, then combination treatment with glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be necessary.",
"   </p>",
"   <p>",
"    Short term improvement in measures of cardiac muscle perfusion and function may result from use of a calcium channel blocking drug. This was illustrated in a two week unblinded study in 18 patients who were examined with cardiac magnetic resonance imaging and Doppler echocardiography before and after a two week trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (20 mg three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/24\">",
"     24",
"    </a>",
"    ]. Whether or not such short-term improvements in perfusion and systolic and diastolic function are associated with better long-term outcomes is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Genitourinary",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erectile dysfunction (ED) is common in men with scleroderma, resulting from impaired penile blood flow due to both myointimal proliferation of small arteries and corporal fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment with on-demand phosphodiesterase type 5 (PDE-5) inhibitors is usually not effective. Greater clinical benefit may be achieved with fixed daily or alternate day regimens of long-acting PDE-5 inhibitors, after addressing modifiable or reversible risk factors for ED, including lifestyle, psychological, or drugs. Consultation with a urologist may be of benefit if other approaches are required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantial increase in the risk of premature death with both dcSSc and lcSSc. This was illustrated by a study of 1733 Scottish patients with autoimmune rheumatic disease followed for up to 20 years; the standardized mortality ratio (SMR) was significantly higher among both men and women with SSc than was expected for a general population of similar ages and gender (SMR 2.7, 95 percent CI 2.14 to 3.38, and SMR 3.81, CI 3.41 to 4.25, for men and women, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall mortality rate of patients with dcSSc is approximately five- to eightfold higher than that of the general population, when adjusted for age and gender. Five and ten-year mortality rates in 185 patients (63 percent with lcSSc) were 10 percent and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/27\">",
"     27",
"    </a>",
"    ]. Most deaths among patients with dcSSC are due to pulmonary fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary hypertension rather than to scleroderma renal crisis, the most common cause of death in past decades [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality due to scleroderma-related cardiac disease, especially heart failure and arrhythmias, is also common, while the most prevalent causes of death that are not directly related to SSc include infections, malignancies and cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/29\">",
"     29",
"    </a>",
"    ]. For patients with limited skin involvement, the increase in the standardized mortality ratio is about twofold.",
"   </p>",
"   <p>",
"    Survival for dcSSc has improved over the past decade; this improvement has been associated with more complete ascertainment of significant internal organ disease, particularly pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Risk factors for increased mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various risk factors have been associated with increased mortality, including the presence of dcSSc, cardiac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal involvement and hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. Risk factors at presentation for mortality in a multiethnic early scleroderma cohort of 250 patients included age of at least 65 years, forced vital capacity of less than 50 percent predicted, significant cardiac arrhythmia, absence of anticentromere antibodies, hypertension, pulmonary fibrosis detected by chest radiography, low body mass index, and the histocompatibility antigens DRB1*0802 and DQA1*0501 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with lcSSc, a worse prognosis is associated with the presence of",
"    <span class=\"nowrap\">",
"     anti-Th/To",
"    </span>",
"    antibodies rather than anticentromere antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Extent of skin involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with scleroderma is related to the extent of skin involvement. Two cohort studies of 1,012 and 309 patients found poorer 10-year survival among those with diffuse skin disease compared to those with limited scleroderma (53 to 62 versus 75 to 79 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A meta-analysis of individual data on 3311 European, Japanese, and North American patients also noted an increased risk of premature death in those with diffuse skin involvement (adjusted hazard ratio 1.2, 95% CI 1.0-1.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among those with diffuse skin involvement, more severe skin sclerosis, as assessed by skin score, is associated with increased mortality. This was illustrated in a study of 225 patients with diffuse skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/36\">",
"     36",
"    </a>",
"    ]. Those with severe involvement (modified Rodnan skin score [MRSS] &ge;35), compared with those with less skin sclerosis (MRSS &lt;35) had significantly greater cumulative mortality (37 versus 21 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension is an adverse predictor in patients with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. As an example, in one retrospective case-control study, 106 patients with SSc (90 percent with lcSSc) who developed symptomatic pulmonary hypertension and manifestations of right sided heart failure, had significantly higher five year mortality rates compared with 106 age, gender, SSc-subtype, and disease-duration matched controls (approximately 90 percent versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/37\">",
"     37",
"    </a>",
"    ]. Characteristics associated with an increased risk of development of symptomatic pulmonary hypertension are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of pulmonary hypertension is correlated with the risk of premature death. This was illustrated in a prospective study of 749 patients, among whom 89 (12 percent) had pulmonary hypertension that was documented by right heart catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/39\">",
"     39",
"    </a>",
"    ]. When patients in the lowest, middle, and highest tertiles (mean PAP &lt;32, 32-44, and &ge;45 mmHg) were compared, the three year survival rates were significantly different (75, 61, and 33 percent, respectively). An elevated mean right atrial pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased cardiac index were other poor prognostic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Risk of radiation therapy for malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have suggested that patients with connective tissue disorders, especially those with SSc, are at greater risk than patients without these disorders for toxic effects from radiotherapy used to treat malignant conditions than are patients without connective tissue disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. The small size of studies in the literature prevents firm conclusions.",
"   </p>",
"   <p>",
"    A systematic review found methodologic shortcomings in most studies and failed to demonstrate convincingly that patients with connective tissue disorders are at increased risk for late radiation-related toxic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/44\">",
"     44",
"    </a>",
"    ]. The risks associated with each specific connective tissue disorder were not analyzed, but similar conclusions were reached in a subsequent retrospective study of 20 SSc patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/20/13642/abstract/45\">",
"     45",
"    </a>",
"    ]. The short-term and long-term rate of grade 3 (severe) toxicity was not excessive compared to other patient cohorts receiving radiotherapy and there were no severe acute skin reactions. There were no cases in which radiotherapy was believed to have exacerbated SSc and the preponderance of deaths were related to the underlying malignancy rather than to SSc.",
"   </p>",
"   <p>",
"    Based upon the data available, SSc does not appear to be a contraindication to radiotherapy, but treatment decisions must be made on an individual basis with careful consideration of the potential risks and benefits of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27624986\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the management of adults with SSc will be discussed here. Pretreatment evaluation and systemic immunologic modulation and potentially antifibrotic approaches are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37045?source=see_link\">",
"     \"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=see_link\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall management of SSc requires a high level of education and encouragement of patients in combination with a team approach to care. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Psychological impact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pruritus may benefit from antihistamines; maintaining adequate lubrication of the skin is important. Facial telangiectasis may benefit from laser therapy, but can be covered with green foundation make-up. Predictably effective treatments for calcinosis are lacking; calcium channel blockers and surgical removal of lesions using a dental drill, as well as other therapies, have been tried. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of localized sclerotic skin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment of widespread skin sclerosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pruritus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Telangiectasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Calcinosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of the Raynaud phenomenon (RP) should be performed in a graduated fashion. therapies only provide symptomatic relief; they do not cure the disease. Treatment of RP in patients with SSc is generally the same as for others with the disorder, although",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      may reduce the frequency of new digital ulcerations in patients with SSc and parenteral prostacyclins may be of benefit. Sympathectomy may be of benefit, but surgery may be required in some patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Raynaud phenomenon'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood pressure, serum creatinine, GFR, urinalysis, and urine protein (24 hour urine or urine",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratio) are helpful to measure initially and to monitor as indicators of renal disease in SSc. Monitoring is most important during the first five years of SSc, since most cases of renal disease occur by this time. Control of blood pressure is the mainstay of treatment of scleroderma renal crisis. Angiotensin converting enzyme (ACE) inhibitors are the first-line antihypertensive agents in this setting. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Renal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of hypertension and renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of gastrointestinal (GI) manifestations is based primarily on symptoms and portion of the GI tract that is affected, although the empiric use of proton pump inhibitors, is generally advised. Gastroesophageal reflux, delayed gastric emptying, intestinal hypomotility, bacterial overgrowth, malabsorption, diarrhea, and fecal incontinence are some of the problems for which treatment is indicated. Prokinetic agents, antibiotics, parenteral nutrition, and surgery may be required in some patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Gastrointestinal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment of GI manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary function tests (including lung volumes and diffusing capacity for carbon monoxide), high-resolution CT scanning are more sensitive tests than plain radiographs of the chest for detection of alveolitis and are recommended to assess pulmonary involvement prior to treatment and at yearly intervals thereafter. We also advise echocardiographic examination of all patients with SSc at baseline and yearly intervals thereafter to detect pulmonary hypertension, with additional monitoring of lung function tests and dyspnea. Clinical suspicion should prompt further assessment by right heart catheterization. &nbsp;Treatment for alveolitis and interstitial disease and treatment for pulmonary hypertension are discussed in detail elsewhere. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Lung'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Interstitial fibrosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthritic symptoms often require analgesia with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      NSAIDs; low-dose glucocorticoids to control the pain and inflammation are infrequently required; physical therapy is important in limiting contractures. Treatment of patients with SSc and an inflammatory myopathy is similar to that for patients with idiopathic polymyositis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Musculoskeletal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Arthralgia and/or arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Inflammatory myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests that are recommended in the presence of symptoms suggesting cardiac involvement include: electrocardiography, plain chest radiograph, serum creatine kinase and troponin-I, and echocardiography. Chest pain due to pericarditis in the absence of evidence of tamponade is treated with an NSAID unless there are contraindications. Pericarditis refractory to NSAIDs and heart failure associated with left ventricular dysfunction may require use of glucocorticoids; cardiac tamponade due to pericarditis typically necessitates drainage of the effusion. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Cardiac'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Pericarditis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29\">",
"       'Myocardial fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erectile dysfunction may require continued therapy with long-acting phosphodiesterase type 5 inhibitors. Modifiable or reversible risk factors should also be identified and treated. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Erectile dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a substantial increase in the risk of premature death with both diffuse cutaneous systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis (lcSSc). Improved survival in dcSSc improvement has been associated with more complete ascertainment of significant internal organ disease, particularly pulmonary involvement. Various risk factors have been associated with increased mortality, including the presence of dcSSc, cardiac",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal involvement and hypertension, as well as the extent of skin involvement and the presence of pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/1\">",
"      LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/2\">",
"      Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/3\">",
"      Stege H, Berneburg M, Humke S, et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/4\">",
"      Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/5\">",
"      Andres C, Kollmar A, Mempel M, et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010; 162:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/6\">",
"      Dutz J. Treatment options for localized scleroderma. Skin Therapy Lett 2000; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/7\">",
"      Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998; 39:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/8\">",
"      Su TI, Khanna D, Furst DE, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009; 60:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/9\">",
"      Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/10\">",
"      McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002; 118:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/11\">",
"      Santiago B, Gutierrez-Ca&ntilde;as I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005; 125:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/12\">",
"      Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum 1995; 38:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/13\">",
"      Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/14\">",
"      Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004; 50:3985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/15\">",
"      Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/16\">",
"      Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/17\">",
"      Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999; 26:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/18\">",
"      Kingdon EJ, Knight CJ, Dustan K, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 2003; 42:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/19\">",
"      Michalets EL, Williams CR. Drug interactions with cisapride: clinical implications. Clin Pharmacokinet 2000; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/20\">",
"      Pigula FA, Griffith BP, Zenati MA, et al. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997; 64:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/21\">",
"      Rosas V, Conte JV, Yang SC, et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/22\">",
"      Jones NF, Imbriglia JE, Steen VD, Medsger TA. Surgery for scleroderma of the hand. J Hand Surg Am 1987; 12:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/23\">",
"      Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/24\">",
"      Vignaux O, Allanore Y, Meune C, et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005; 64:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/25\">",
"      Walker UA, Tyndall A, Ruszat R. Erectile dysfunction in systemic sclerosis. Ann Rheum Dis 2009; 68:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/26\">",
"      Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/27\">",
"      Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010; 39:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/28\">",
"      Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/29\">",
"      Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/30\">",
"      Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/31\">",
"      Assassi S, Del Junco D, Sutter K, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009; 61:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/32\">",
"      Mitri GM, Lucas M, Fertig N, et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003; 48:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/33\">",
"      Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/34\">",
"      Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/35\">",
"      Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/36\">",
"      Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/37\">",
"      Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/38\">",
"      Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/39\">",
"      Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/40\">",
"      Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol 1997; 15:2728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/41\">",
"      Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001; 7:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/42\">",
"      Phan C, Mindrum M, Silverman C, et al. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. Cancer J 2003; 9:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/43\">",
"      Lin A, Abu-Isa E, Griffith KA, Ben-Josef E. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer 2008; 113:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/44\">",
"      H&ouml;lscher T, Bentzen SM, Baumann M. Influence of connective tissue diseases on the expression of radiation side effects: a systematic review. Radiother Oncol 2006; 78:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/20/13642/abstract/45\">",
"      Gold DG, Miller RC, Petersen IA, Osborn TG. Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2007; 67:559.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7542 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-741DB5ED1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13642=[""].join("\n");
var outline_f13_20_13642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27624986\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSYCHOLOGICAL IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMMUNOMODULATORY AND ANTIFIBROTIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ORGAN BASED TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment of localized sclerotic skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment of widespread skin sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Calcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vascular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Future directions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Treatment of hypertension and renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Treatment of GI manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Interstitial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Arthralgia and/or arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Inflammatory myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Myocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Risk factors for increased mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Extent of skin involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Risk of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27624986\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7542|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/39/32383\" title=\"algorithm 1\">",
"      Rx scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/22/1388\" title=\"table 1\">",
"      Localized scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/41/3741\" title=\"table 2\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/18/10541\" title=\"table 3\">",
"      Autoantibodies in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/57/23453\" title=\"table 4\">",
"      Rx of Raynauds Phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/26/43436\" title=\"table 5\">",
"      Potential Rx in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23849?source=related_link\">",
"      Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39433?source=related_link\">",
"      Juvenile systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=related_link\">",
"      Pathogenesis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/11/37045?source=related_link\">",
"      Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11177?source=related_link\">",
"      Recurrent pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9958?source=related_link\">",
"      Surgery in patients with systemic sclerosis (scleroderma) of the hand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11415?source=related_link\">",
"      Treatment of gastrointestinal disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17640?source=related_link\">",
"      Treatment of morphea (localized scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_20_13643="NCI CTCAE grading for palmar plantar erythrodysesthesia syndrome";
var content_f13_20_13643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events (CTCAE) grading scale for palmar plantar erythrodysesthesia syndrome (v 4.03)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Minimal skin changes or dermatitis (eg, erythema, edema, or hyperkeratosis) without pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting instrumental ADL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Severe skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain, limiting self-care ADL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.03, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13643=[""].join("\n");
var outline_f13_20_13643=null;
var title_f13_20_13644="Causes of esophageal dysphagia";
var content_f13_20_13644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of esophageal dysphagia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mechanical lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intrinsic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caustic esophagitis/stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diverticula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peptic stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eosinophilic esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pill esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post surgery (laryngeal, esophageal, gastric)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Radiation esophagitis/stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rings and webs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphocytic esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Extrinsic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aberrant subclavian artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cervical osteophytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enlarged aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enlarged left atrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mediastinal mass (lymphadenopathy, lung cancer, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post surgery (laryngeal, spinal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Motility disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Achalasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chagas' disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary motility disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary motility disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional dysphagia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13644=[""].join("\n");
var outline_f13_20_13644=null;
var title_f13_20_13645="Free water clearance";
var content_f13_20_13645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76658&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Free water clearance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 203px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Block diagram showing the relationship in a dilute urine between the urine volume and its two components: one containing all of the urinary solute in a solution that is isosmotic to plasma (the osmolal clearance); and one consisting of solute-free water (the free water clearance).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Rose, BD, Am J Med 1986; 81:1033.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13645=[""].join("\n");
var outline_f13_20_13645=null;
var title_f13_20_13646="Contents: Neurodegenerative disease";
var content_f13_20_13646=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurodegenerative disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurodegenerative disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/55/1913\">",
"           Cholinesterase inhibitors in the treatment of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/55/1914\">",
"           Clinical features and diagnosis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27162\">",
"           Clinical manifestations and diagnosis of Alzheimer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/41/34455\">",
"           Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/57/37786\">",
"           Etiology, clinical manifestations, and diagnosis of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28057\">",
"           Evaluation of cognitive impairment and dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/20/12618\">",
"           Frontotemporal dementia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/21/32089\">",
"           Genetics of Alzheimer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27161\">",
"           Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/33/26138\">",
"           Mild cognitive impairment: Prognosis and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/26/14762\">",
"           Normal pressure hydrocephalus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/36/15946\">",
"           Parkinson disease dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41369\">",
"           Prevention of dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/34/21031\">",
"           Prognosis and treatment of dementia with Lewy bodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36202\">",
"           Risk factors for dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/28/4552\">",
"           Safety and societal issues related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10104\">",
"           Treatment and prevention of vascular dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27402\">",
"           Treatment of behavioral symptoms related to dementia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33865\">",
"           Treatment of dementia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parkinson's disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/17/21784\">",
"           Management of comorbid problems associated with Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/26/18857\">",
"           Motor fluctuations and dyskinesia in Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4277\">",
"           Nonpharmacologic management of Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/63/32762\">",
"           Pharmacologic treatment of Parkinson disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/22/32105\">",
"           Surgical treatment of Parkinson disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/54/7017\">",
"           Biology and genetics of prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/62/30698\">",
"           Creutzfeldt-Jakob disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/28/31176\">",
"           Diseases of the central nervous system caused by prions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40728\">",
"           Variant Creutzfeldt-Jakob disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/25/408\">",
"           Frontotemporal dementia: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-DE9B3AC616-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f13_20_13646=[""].join("\n");
var outline_f13_20_13646=null;
var title_f13_20_13647="Retinal blot hemorrhages";
var content_f13_20_13647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retinal blot hemorrhages: Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diabetic retinopathy, showing several blot hemorrhages (arrows). These lesions are due to vascular occlusion and rupture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_20_13647=[""].join("\n");
var outline_f13_20_13647=null;
